prof. dr. med. hans-joachim schmoll pubmed 1970 – 2018 · if: 0, anteiliger if: 0 1985 summe...

Prof. Dr. med. Hans-Joachim Schmoll PubMed 1970 – 2018

N Publications; 445 Cumulative Impact Factor: 1697

Web of Science: h (Hirsch-) Factor: 71

Journalbeitrag Originalarbeiten

1. Schwoon DR, Schmoll HJ: (1979) Motivation to participate in cancer screening

programmes. SOC SCI MED, 13: 283-6. IF: 0, anteiliger IF: 0

1979 Summe Bewertung = 0

Originalarbeiten

1. Schmoll HJ, Niederle N, Achterrath W: (1981) [Etoposide VP 16--213)--a

podophyllotoxinderivative with high antitumor activity (author's transl)]. KLIN

WOCHENSCHR, 59: 1177-88. 7031350 IF: 0, anteiliger IF: 0


Originalarbeiten

1. Weiss J, von Roemeling R, Peters HD, Schmoll HJ, Diehl V: (1983) [Chemotherapy in

pretreated Hodgkin's disease with lomustine, bleomycin, vinblastine and

dexamethasone]. DEUT MED WOCHENSCHR, 108: 1428-32. 6192987 IF: 0, anteiliger IF: 0


Originalarbeiten

1. Gabius HJ, Engelhardt R, Casper J, Reile D, Schumacher S, Schmoll HJ, Graupner G,

Cramer F: (1985) Cell surface lectins of transplantable human teratocarcinoma cells:

purification of a new mannan-specific endogenous lectin. TUMOR BIOL, 6: 145-

56. 4048775

IF: 0, anteiliger IF: 0


Originalarbeiten

1. Gabius HJ, Engelhardt R, Casper J, Schmoll HJ, Nagel GA, Cramer F: (1986)

Comparison of endogenous lectins in human embryonic carcinoma and yolk sac

carcinoma. TUMOR BIOL, 6: 471-82. 3010437 IF: 0, anteiliger IF: 0

2. Peest D, Schmoll HJ, Schedel I, Deicher H, Boll J, Essers U, Gamm H, Gluck S, Gorg K,

Gramatzki M, et A: (1986) Current results of a multicenter trial in multiple myeloma.

ONKOLOGIE, 9: 168-9. 3528964 IF: 0, anteiliger IF: 0

1986 Summe Bewertung = 0 Summe IF = 0

Originalarbeiten

1. Berdel WE, Berger MR, Falk H, Harstrick A, Danhauser S, Schick HD, Schmoll HJ,

Schmahl D, Vogler WR, Rastetter J: (1987) Lack of therapeutic activity of the lipoidal

amine CP-46,665 in rodent tumors and human non-seminomatous germ cell tumors

growing in nude mice. CANCER LETT, 38: 191-7. 2825966 IF: 0, anteiliger IF: 0

2. Casper J, Schmoll HJ, Schnaidt U, Fonatsch C: (1987) Cell lines of human germinal

cancer. INT J ANDROL, 10: 105-13. 3034787 IF: 0, anteiliger IF: 0

3. Creutzig A, Polking W, Schmoll HJ, Fabel H, Alexander K: (1987) [Raynaud syndrome

and changes in lung function as sequelae of cytostatic therapy of testicular tumors].

MED KLIN-INTENSIVMED, 82: 131-4. 2436030 IF: 0, anteiliger IF: 0

4. Gabius HJ, Bokemeyer C, Hellmann T, Schmoll HJ: (1987) Targeting of

neoglycoprotein-drug conjugates to cultured human embryonal carcinoma cells. J

CANCER RES CLIN, 113: 126-30. 3031079 IF: 0, anteiliger IF: 0

5. Harstrick A, Casper J, Schmoll HJ: (1987) Comparative antitumour activity of cisplatin

and two new cisplatin-analogues JM8 and JM9 in human testicular carcinoma

xenografts. INT J ANDROL, 10: 139-45. 3034790 IF: 0, anteiliger IF: 0

6. Schmoll HJ, Schubert I, Arnold H, Dolken G, Hecht T, Bergmann L, Illiger J, Fink U,

Preiss J, Pfreundschuh M, et A: (1987) Disseminated testicular cancer with bulky

disease: results of a phase-II study with cisplatin ultra high dose/VP-16/bleomycin.

INT J ANDROL, 10: 311-7. 2438224 IF: 0, anteiliger IF: 0


Originalarbeiten

1. Calavrezos A, Koschel G, Husselmann H, Taylessani A, Heilmann HP, Fabel H, Schmoll

HJ, Dietrich H, Hain E: (1988) Malignant mesothelioma of the pleura. A prospective

therapeutic study of 132 patients from 1981-1985. KLIN WOCHENSCHR, 66: 607-

13. 3210656 IF: 0, anteiliger IF: 0

2. Peest D, Schmoll HJ, Schedel I, Gluck S, Schumacher K, Deicher H: (1988) VBAMDex

chemotherapy in advanced multiple myeloma. EUR J HAEMATOL, 40: 245-9. 3356240 IF: 0, anteiliger IF: 0

3. Verbeek W, Bokemeyer C, Falk H, Schmoll HJ: (1988) Growth requirements, growth

factor responsiveness, and growth factor secretion of three human embryonal

carcinoma cell lines. J CANCER RES CLIN, 114: 553-8. 3204101 IF: 0, anteiliger IF: 0

4. Wilke H, Achterrath W, Schmoll HJ, Gunzer U, Preusser P, Lenaz L: (1988) Etoposide

and split-dose cisplatin in small-cell lung cancer. AM J CLIN ONCOL-CANC, 11: 572-


5. Wilke H, Schmoll HJ, Preusser P, Fink U, Stahl M, Schober C, Link H, Freund M,

Hanauske A, Meyer HJ, et A: (1988) Folinic acid (CF)/5-fluorouracil (FUra)

combinations in advanced gastrointestinal carcinomas. ADV EXP MED BIOL, 244: 233-


6. Wilke H, Schmoll HJ, Schober C, Stahl M, Preusser P, Freund M, Poliwoda H: (1988)

Folinic acid (FA) plus 5-fluorouracil (FU) in progressive advanced colorectal cancer.

BIOMED PHARMACOTHER, 42: 373-80. 3064821 IF: 0, anteiliger IF: 0


Originalarbeiten

1. Arnemann J, Gradl G, Casper J, Schmoll HJ, Schmidtke J, Fonatsch C: (1989)

Characterization of rearranged Y chromosomes in human testicular tumor cell lines.

CANCER GENET CYTOGEN, 37: 141-51. 2539248 IF: 0, anteiliger IF: 0

2. Bokemeyer B, Grote R, Schmoll E, Freise J, Schmoll HJ, Galanski M, Schuler A, Schmidt

FW: (1989) [Chemoembolization of hepatocellular carcinoma with lipiodol, epirubicin

and cisplatin]. DEUT MED WOCHENSCHR, 114: 128-32. 2536606 IF: 0, anteiliger IF: 0

3. Harstrick A, Casper J, Guba R, Wilke H, Poliwoda H, Schmoll HJ: (1989) Comparison of

the antitumor activity of cisplatin, carboplatin, and iproplatin against established

human testicular cancer cell lines in vivo and in vitro. CANCER-AM CANCER SOC, 63:

1079-83. 2645036 IF: 0, anteiliger IF: 0

4. Schmoll HJ: (1989) The role of ifosfamide in testicular cancer. SEMIN ONCOL, 16(1

Suppl 3): 82-95. 2649987 IF: 0, anteiliger IF: 0

5. Winkler K, Torggler S, Beron G, Bode U, Gerein V, Jurgens H, Kusnierz-Glaz C, Kotz R,

Salzer-Kuntschik M, Schmoll HJ, et A: (1989) [Results of treatment in primary

disseminated osteosarcoma. Analysis of the follow-up of patients in the cooperative

osteosarcoma studies COSS-80 and COSS-82]. ONKOLOGIE, 12: 92-6. 2660050 IF: 0, anteiliger IF: 0


Originalarbeiten

1. Harstrick A, Casper J, Kohne-Wompner H, Wilke H, Schmoll HJ, Poliwoda H: (1990)

Comparative activity of four anthracyclines against heterotransplanted germ cell

tumor lines. INVEST NEW DRUG, 8: S19-24. 1696245 IF: 0, anteiliger IF: 0

2. Harstrick A, Schmoll HJ, Casper J, Wilke H, Poliwoda H: (1990) Activity of cytostatic

drugs in two heterotransplanted human testicular cancer cell lines with different

sensitivity to standard agents. EUR J CANCER, 26: 898-901. 2145935 IF: 0, anteiliger IF: 0

3. Harstrick A, Schmoll HJ, Wilke H, Schober C, Stahl M, Wompner CK, Bokemeyer C,

Dolken G, Burk K, Poliwoda H: (1990) High dose epirubicin in refractory or relapsed

non-seminomatous testicular cancer: a phase II study. ANN ONCOL, 1: 375-


4. Jackle-Meyer I, Gwinner W, Baum M, Soose M, Petzoldt R, Schmoll HJ, Stolte H:

(1990) Significance of Tamm-Horsfall protein excretion in diabetes mellitus and

cisplatin nephrotoxicity. CONTRIB NEPHROL, 83: 124-9. 2100702 IF: 0, anteiliger IF: 0

5. Preusser P, Wilke H, Achterrath W, Lenaz L, Stahl M, Casper J, Meyer HJ, Meyer J,

Blum M, Schmoll HJ: (1990) Phase II study of carboplatin in untreated inoperable

advanced stomach cancer. EUR J CANCER, 26: 1108-9. 2148891


6. Schmoll HJ: (1990) Progress in treatment of testicular cancer. J CANCER RES CLIN,

116: 112-5. 2312601 IF: 0, anteiliger IF: 0

7. Schmoll HJ, Harstrick A, Kohne-Wompner CH, Schober C, Wilke H, Poliwoda H: (1990)

Modulation of cytotoxic drug activity by dipyridamole. CANCER TREAT REV, 17: 57-


8. Tesch H, Furbass R, Casper J, Lyons J, Bartram CR, Schmoll HJ, Bronson DL: (1990)

Cellular oncogenes in human teratocarcinoma cell lines. INT J ANDROL, 13: 377-



Originalarbeiten

1. Harstrick A, Schmoll HJ, Bokemeyer C, Metzner B, Illiger HJ, Berdel W, Ostermann H,

Manegold C, Rath U, Siegert W, et A: (1991) Cisplatin/etoposide/ifosfamide stepwise

dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor

for patients with far-advanced testicular carcinoma. J CANCER RES CLIN, 117: S198-

202. 1665492 IF: 0, anteiliger IF: 0

2. Harstrick A, Schmoll HJ, Kohne-Wompner CH, Bergmann L, Lammers U, Hohnloser J,

Dolken G, Reichhardt P, Siegert W, Natt F, et A: (1991) Cisplatin, etoposide,

ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced

testicular carcinoma. ANN ONCOL, 2: 197-202. 1710481 IF: 0, anteiliger IF: 0

3. Harstrick A, Schmoll HJ, Wilke H, Kohne-Wompner CH, Stahl M, Schober C, Casper J,

Bruderek L, Schmoll E, Bokemeyer C, et A: (1991) Cisplatin, etoposide, and ifosfamide

salvage therapy for refractory or relapsing germ cell carcinoma. J CLIN ONCOL, 9:

1549-55. 1651992 IF: 0, anteiliger IF: 0

4. Schmoll E, Wilke H, Thole R, Preusser P, Wildfang I, Schmoll HJ: (1991) Megestrol

acetate in cancer cachexia. SEMIN ONCOL, 18(1 Suppl 2): 32-4. 1992534 IF: 0, anteiliger IF: 0

5. Schmoll HJ: (1991) How should we treat disseminated seminoma? ANN ONCOL, 2:

623-4. 1742217 IF: 0, anteiliger IF: 0

6. Schmoll HJ: (1991) Introduction: the clinical challenge. EUR J CANCER, 27: S1-

2. 1831627


7. Schuppert F, Scheumann GFW, Schöber C, Overbeck J, Schürmeyer T, Schmoll HJ,

Dralle H, von zur Mühlen A: (1991) Therapie eines malignen sympathischen

Paraganglioms des Zuckerkandlschen Organs - ein Fallbericht. KLIN WOCHENSCHR,

69: 937 - 942 IF: 0, anteiliger IF: 0

8. Wilke H, Preusser P, Stahl M, Harstrick A, Meyer HJ, Achterrath W, Schmoll HJ,

Seeber S: (1991) Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated

patients with advanced gastric cancer. CANCER CHEMOTH PHARM, 29: 83-4. 1742854 IF: 0, anteiliger IF: 0


Originalarbeiten

1. Bokemeyer C, Freund M, Schmoll HJ, Rieder H, Fonatsch C: (1992) Secondary

lymphoblastic leukemia following treatment of a malignant germ cell tumour. ANN

ONCOL, 3: 772. 1280461 IF: 0, anteiliger IF: 0

2. Bokemeyer C, Harstrick A, Schmoll HJ, Kohne-Wompner CH, Schoffski P, Poliwoda H:

(1992) Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of

metastatic soft tissue sarcomas. ANN ONCOL, 3: 487-8. 1498067 IF: 0, anteiliger IF: 0

3. Bokemeyer C, Harstrick A, Schoffski P, Schmoll HJ, Poliwoda H: (1992) [Germ-cell

tumors of the testis. The epidemiological and etiological aspects]. DEUT MED

WOCHENSCHR, 117: 1532-7. 1327710 IF: 0, anteiliger IF: 0

4. Galanski M, Schmoll E, Reichelt S, Bohmer G, Prokop M, Schaefer C, Schuler A, Ringe

B, Schmidt FW, Schmoll HJ: (1992) [Chemoembolization of hepatocellular carcinoma

in cases of isolated liver involvement]. RADIOLOGE, 32: 49-55. 1314400 IF: 0, anteiliger IF: 0

5. Harstrick A, Bokemeyer C, Preusser P, Kohne-Wompner CH, Meyer HJ, Stahl M, Knipp

H, Schmoll HJ, Wilke H: (1992) Phase II study of single-agent etoposide in patients

with metastatic squamous-cell carcinoma of the esophagus. CANCER CHEMOTH

PHARM, 29: 321-2. 1537080 IF: 0, anteiliger IF: 0

6. Kohne-Wompner CH, Schmoll HJ, Harstrick A, Rustum YM: (1992) Chemotherapeutic

strategies in metastatic colorectal cancer: an overview of current clinical trials. SEMIN

ONCOL, 19(2 Suppl 3): 105-25. 1373004 IF: 0, anteiliger IF: 0

7. Schmoll HJ, Bokemeyer C, Harstrick A, Illiger HJ, Metzner B, Ruther U, Osternamm A,

Preiss J, Wilke H, Hohnloser J, et A: (1992) Dose escalation of cisplatin (P), etoposide

(E), and ifosfamide (I) with GM-CSF for advanced germ cell tumors. PATHOL BIOL, 39:

961. 1538953 IF: 0, anteiliger IF: 0

8. Schmoll HJ, Hiddemann W, Rustum Y, Kohne-Wompner CH: (1992) The emerging role

for biomodulation of antineoplastic agents. SEMIN ONCOL, 19(2 Suppl 3): 1-


9. Schmoll HJ, Kohne-Wompner CH, Hiddemann W, Knipp H, Wilke H, Bodenstein H,

Schoffski P, Bokemeyer C, Lohrmann HP, Preiss J, et A: (1992) Interferon alpha-2b, 5-

fluorouracil, and folinic acid combination therapy in advanced colorectal cancer:

preliminary results of a phase I/II trial. SEMIN ONCOL, 19(2 Suppl 3): 191-6. 1557646 IF: 0, anteiliger IF: 0

10. Schober C, Bokemeyer C, Stahl M, Wilke HJ, Schmoll HJ, Poliwoda H: (1992) The role

of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced

colorectal cancer. SEMIN ONCOL, 19(2 Suppl 3): 131-5. 1557638 IF: 0, anteiliger IF: 0

11. Schober C, Kohne-Wompner CH, Schmoll HJ, Stahl M, Wilke HJ, Poliwoda H: (1992) A

3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal

cancer and its impact in terms of palliation. SEMIN ONCOL, 19(2 Suppl 3): 136-


12. Schober C, Schmoll E, Schmoll HJ, Poliwoda H, Schuppert F, Stahl M, Bokemeyer C,

Wilke H, Weiss J: (1992) Antitumour effect and symptomatic control with interferon

alpha 2b in patients with endocrine active tumours. EUR J CANCER, 28: 1664-


13. Stahl M, Wilke HJ, Seeber S, Schmoll HJ: (1992) Cytokines and cytotoxic agents in

renal cell carcinoma: a review. SEMIN ONCOL, 19(2 Suppl 4): 70-9. 1553577 IF: 0, anteiliger IF: 0

14. Stahl M, Wilke H, Schmoll HJ, Schober C, Diedrich H, Casper J, Freund M, Poliwoda H:

(1992) A phase II study of high dose tamoxifen in progressive, metastatic renal cell

carcinoma. ANN ONCOL, 3: 167-8. 1606089 IF: 0, anteiliger IF: 0

15. Wilke H, Stahl M, Schmoll HJ, Preusser P, Fink U, Meyer HJ, Achterrath W, Knipp H,

Kohne-Wompner CH, Harstrick A, et A: (1992) Biochemical modulation of 5-

fluorouracil by folinic acid or alpha-interferon with and without other cytostatic

drugs in gastric, esophageal, and pancreatic cancer. SEMIN ONCOL, 19(2 Suppl 3):

215-9. 1557651 IF: 0, anteiliger IF: 0


Originalarbeiten

1. Bokemeyer C, Kuczyk M, Schoffski P, Schmoll HJ: (1993) Familial occurrence of Leydig

cell tumors: a report of a case in a father and his adult son. J UROLOGY, 150(5 Pt 1):

1509-10. 8411441 IF: 0, anteiliger IF: 0

2. Bokemeyer C, Luer M, Schmoll HJ, Freund M, Poliwoda H: (1993) Secondary cancer

following Hodgkin's disease. ANN ONCOL, 4: 520-1. 8353097 IF: 0, anteiliger IF: 0

3. Bokemeyer C, Schmoll HJ: (1993) Treatment of advanced germ cell tumours by dose

intensified chemotherapy with haematopoietic growth factors or peripheral blood

stem cells (PBSC). EUR UROL, 23: 223-9; discussion 230. 8097467 IF: 0, anteiliger IF: 0

4. Bokemeyer C, Schmoll HJ: (1993) Treatment strategies in metastatic testicular cancer.

EUR UROL, 23: 50-2. 8390363 IF: 0, anteiliger IF: 0

5. Bokemeyer C, Schmoll HJ: (1993) Secondary neoplasms following treatment of

malignant germ cell tumors. J CLIN ONCOL, 11: 1703-9. 8394879 IF: 0, anteiliger IF: 0

6. Bokemeyer C, Schmoll HJ, Harstrick A: (1993) Side-effects of GM-CSF treatment in

advanced testicular cancer. EUR J CANCER, 29: 924. 8484987 IF: 0, anteiliger IF: 0

7. Bokemeyer C, Schmoll HJ, Harstrick A, Illiger HJ, Metzner B, Rath U, Hohnloser J,

Clemm C, Berdel W, Siegert W, et A: (1993) A phase I/II study of a stepwise dose-

escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-

macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell

tumours. EUR J CANCER, 29: 2225-31. 8110490 IF: 0, anteiliger IF: 0

8. Bokemeyer C, Schmoll HJ, Metzner B, Beyer J, Illiger HJ, Kneba M, Ostermann H,

Kynast B, Rath U, Poliwoda H: (1993) Comparison of 5 vs 10 micrograms/kg per day

of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and

ifosfamide in patients with advanced testicular cancer. ANN HEMATOL, 67: 75-


9. Bokemeyer C, Schmoll HJ, Schoffski P, Harstrick A, Bading M, Poliwoda H: (1993)

Bilateral testicular tumours: prevalence and clinical implications. EUR J CANCER, 29:

874-6. 8387319 IF: 0, anteiliger IF: 0

10. Erlichman C, Fine S, Kerr I, Hoffman W, Gorg C, Schmoll HJ, Preusser P, Senn HJ,

Gustavsson B: (1993) Experience with 5FU + L-leucovorin. ADV EXP MED BIOL, 339:

77-9; discussion 97-8. 8178731 IF: 0, anteiliger IF: 0

11. Grigor KM, Schmoll HJ: (1993) How should we identify high risk testicular tumour

patients? Round table discussion. EUR UROL, 23: 207-12. 8386651 IF: 0, anteiliger IF: 0

12. Grigor KM, Schmoll HJ: (1993) Should high dose chemotherapy with, or without,

autologous bone marrow transplant be included in the primary treatment of

testicular cancer? Round table discussion. EUR UROL, 23: 240-4. 8386655 IF: 0, anteiliger IF: 0

13. Grundner-Culemann E, Bokemeyer C, Neubauer V, Shalitin C, Schmoll HJ, Poliwoda H,

Benter T: (1993) Analysis of a non-ras 21-kDa protein in patients with metastatic

testicular germ-cell tumors. J CANCER RES CLIN, 119: 685-8. 8394368 IF: 0, anteiliger IF: 0

14. Harstrick A, Bokemeyer C, Scharnofkse M, Hapke G, Reile D, Schmoll HJ: (1993)

Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -

resistant human testicular, ovarian, and gastric carcinoma cell lines. CANCER

CHEMOTH PHARM, 33: 43-7. 8269588 IF: 0, anteiliger IF: 0

15. Harstrick A, Bokemeyer C, Schmoll HJ, Kohne-Wompner CH, Knipp H, Schoffski P,

Anagnou J, Wipperman B, Neumann S, Poliwoda H: (1993) A pilot study of rapidly

alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic

soft-tissue sarcoma in adults. CANCER CHEMOTH PHARM, 31: S217-21. 8453702 IF: 0, anteiliger IF: 0

16. Harstrick A, Schmoll HJ, Sass G, Poliwoda H, Rustum Y: (1993) Titanocendichloride

activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines.

EUR J CANCER, 29: 1000-2. 8499130 IF: 0, anteiliger IF: 0

17. Kohne-Wompner CH, Schmoll HJ: (1993) 5-Fluorouracil modulation in colorectal

carcinoma experience of German investigators. ADV EXP MED BIOL, 339: 99-

107. 8178734 IF: 0, anteiliger IF: 0

18. Kynast B, Binder L, Marx D, Zoll B, Schmoll HJ, Oellerich M, Schauer A: (1993)

Determination of a fragment of the c-erbB-2 translational product p185 in serum of

breast cancer patients. J CANCER RES CLIN, 119: 249-52. 8095050 IF: 0, anteiliger IF: 0

19. Schmoll HJ, Harstrick A, Bokemeyer C, Dieckmann KP, Clemm C, Berdel WE, Souchon

R, Schober C, Wilke H, Poliwoda H: (1993) Single-agent carboplatinum for advanced

seminoma. A phase II study. CANCER-AM CANCER SOC, 72: 237-43. 8508413


20. Schmoll HJ, Seeber S: (1993) [Current developments in chemotherapy of advanced

testicular tumors]. UROLOGE, 32: 207-16. 8511834 IF: 0, anteiliger IF: 0


Originalarbeiten

1. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W: (1994) Treatment intensification in

disseminated germ-cell tumors. WORLD J UROL, 12: 207-13. 7820143 IF: 0,561, anteiliger IF: 0,09352

2. Bokemeyer C, Dunn T, Harstrick A, Lerch T, Poliwoda H, Schmoll HJ: (1994)

Modulation of cytostatic drugs by nifedipine in two heterotransplanted human

testicular-cancer cell lines differing in their sensitivity to standard agents. INT J

CANCER, 56: 452-6. 7906255 IF: 3,276, anteiliger IF: 1,09189

3. Bokemeyer C, Harstrick A, Ruther U, Metzner B, Illiger HJ, Clemm C, Siegert W, Link H,

Ostermann H, Schmoll HJ: (1994) The role of granulocyte-macrophage colony-

stimulating factor in the treatment of germ cell tumors. German Testicular Cancer

Study Group. SEMIN ONCOL, 21(6 Suppl 16): 57-63. 7801148 IF: 2,628, anteiliger IF: 0,87591

4. Bokemeyer C, Harstrick A, Schmoll HJ: (1994) The use of carboplatin in malignant

germ cell tumours. EUR J CANCER, 30: 721-2. 8080698 IF: 0,789, anteiliger IF: 0,26297

5. Bokemeyer C, Schmoll HJ, Ludwig E, Harstrick A, Dunn T, Casper J: (1994) The anti-

tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines

remains unaltered by the uroprotector mesna. BRIT J CANCER, 69: 863-7. 8180015 IF: 3,188, anteiliger IF: 0,26572

6. Bokemeyer C, Schmoll HJ, Natt F, Knoche M, Beyer J, Souchon R: (1994) Preliminary

results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-

refractory testicular cancer. J CANCER RES CLIN, 120: 754-7. 7798304 IF: 1,654, anteiliger IF: 0,13786

7. Bokemeyer C, Schmoll HJ, Poliwoda H: (1994) [Secondary leukemias after etoposide

chemotherapy]. DEUT MED WOCHENSCHR, 119: 707-13. 8187625 IF: 0,605, anteiliger IF: 0,20171

8. Bokemeyer C, Schmoll HJ, van Rhee J, Kuczyk M, Schuppert F, Poliwoda H: (1994)

Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma.

ANN HEMATOL, 68: 105-10. 8167175 IF: 1,496, anteiliger IF: 0,12469

9. Derigs HG, Huber C, Schmoll HJ: (1994) [Stage-oriented therapy in nonseminomatous

testicular tumors]. DEUT MED WOCHENSCHR, 119: 156-64. 8313845 IF: 0,605, anteiliger IF: 0,20165

10. Hill BT, Shellard SA, Fichtinger-Schepman AM, Schmoll HJ, Harstrick A: (1994)

Differential formation and enhanced removal of specific cisplatin-DNA adducts in two

cisplatin-selected resistant human testicular teratoma sublines. ANTI-CANCER DRUG,

5: 321-8. 7919457 IF: 1,258, anteiliger IF: 0,13981

11. Kohne-Wompner CH, Schoffski P, Schmoll HJ: (1994) Adjuvant therapy for colon

adenocarcinoma: current status of clinical investigation. ANN ONCOL, 5: 97-

104. 8204538 IF: 1,914, anteiliger IF: 0,63794

12. Link H, Herrmann F, Welte K, Aulitzky WE, Ganser A, Kern WV, Meyer P, Schrappe M,

Schmoll HJ, Werdan K, et A: (1994) [Rational therapy with G-CSF and GM-CSF]. MED

KLIN-INTENSIVMED, 89: 429-41. 7526144 IF: 0, anteiliger IF: 0

13. Schmoll HJ: (1994) Colorectal carcinoma: current problems and future perspectives.

ANN ONCOL, 5: 115-21. 8204526 IF: 1,914, anteiliger IF: 1,914

14. Schmoll HJ: (1994) [Adjuvant chemotherapy in rectal cancer]. CHIRURG, 65: 576-

84. 7924595 IF: 0,657, anteiliger IF: 0,657

15. Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, Zimmermann R,

Bokemeyer C, Schmoll HJ, Huhn D: (1994) High-dose treatment with carboplatin,

etoposide, and ifosfamide followed by autologous stem-cell transplantation in

relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular

Cancer Cooperative Study Group. J CLIN ONCOL, 12: 1223-31. 7911158 IF: 7,507, anteiliger IF: 0,31285

1994 Summe Bewertung = 6,91752 Summe IF = 28,052

Originalarbeiten

1. Bajorin DF, Nichols CR, Schmoll HJ, Kantoff PW, Bokemeyer C, Demetri GD, Einhorn

LH, Bosl GJ: (1995) Recombinant human granulocyte-macrophage colony-stimulating

factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for

patients with advanced or relapsed germ cell tumors: a randomized trial. J CLIN

ONCOL, 13: 79-86. 7799046 IF: 6,922, anteiliger IF: 0,38463

2. Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ: (1995) Secondary

Raynaud's phenomenon and other late vascular complications following

chemotherapy for testicular cancer. EUR J CANCER, 31: 2229-38. 8652248

IF: 2,095, anteiliger IF: 0,69826

3. Bokemeyer C, Kynast B, Harstrick A, Laage E, Schmoll E, von Wussow P, Schmoll HJ:

(1995) No synergistic activity of epirubicin and interferon-alpha 2b in the treatment

of hepatocellular carcinoma. CANCER CHEMOTH PHARM, 35: 334-8. 7828277 IF: 1,598, anteiliger IF: 0,53261

4. Bokemeyer C, Ludwig E, Reile D, Harstrick A, Poliwoda H, Schmoll HJ: (1995)

Antitumour activity and toxicity of continuous infusion versus bolus administration of

bleomycin in two heterotransplanted human testicular cancer cell lines. ONCOL REP,

2: 161-165 IF: 0,421, anteiliger IF: 0,14032

5. Bokemeyer C, Schmoll HJ: (1995) Treatment of testicular cancer and the

development of secondary malignancies. J CLIN ONCOL, 13: 283-92. 7799032 IF: 6,922, anteiliger IF: 3,461

6. Bokemeyer C, Schmoll HJ: (1995) Sekundärneoplasien nach der Therapie maligner

Keimzelltumoren des Hodens. STRAHLENTHER ONKOL, 6: 356-357 IF: 0, anteiliger IF: 0

7. Bokemeyer C, Schmoll HJ, Kuczyk MA, Beyer J, Siegert W: (1995) Risk of secondary

leukemia following high cumulative doses of etoposide during chemotherapy for

testicular cancer. JNCI-J NATL CANCER I, 87: 58-60. 7666466 IF: 10,165, anteiliger IF: 1,12967

8. Köhne CH, Hiddemann W, Schüller J, Weiss J, Lorhmann HP, Schmitz-Hübner U,

Bodenstein H, Schöber C, Wilke H, Grem J, Schmoll HJ: (1995) Failure of orally

administered Dipyridamole to enhance the antineoplastic activity for Fluorouracil in

combination with Leucovorin in patients with advanced colorectal cancer: a

prospective randomized trial. J CLIN ONCOL, 13: 1201-1208 IF: 6,922, anteiliger IF: 2,3071

9. Köhne CH, Schmoll HJ: (1995) Therapiestudien zur adjuvanten und palliativen

Therapie. ONKOLOGE, 1: 57-60 IF: 0, anteiliger IF: 0

10. Köhne CH, Schmoll HJ, Wilke H, Käufer C, Rauschecker H, Andreesen R, Ohl U, Lange

HJ, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Bade J, Strohmeyer G,

Schöffski P, Schubert U, Hecker H: (1995) Interferon-alpha does not improve the

antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in

advanced colorectal cancer: First results of a randomized multicenter study by the

Association of Medical Oncology of the German Cancer Society (AIO). ANN ONCOL, 6:

461-466 IF: 2,256, anteiliger IF: 0,05014

11. Kuczyk MA, Bokemeyer C, Fichna B, Truss M, Schmoll HJ, Jonas U: (1995)

[Differentiated teratoma as late recurrence of metastatic non-seminomatous

testicular germ cell tumor. Case report and clinical problems]. UROLOGE, 34: 480-

4. 8848861


12. Kuczyk MA, Bokemeyer C, Schmoll HJ, Jonas U: (1995) The prognostic role of

alterations of the p53 tumor suppressor gene in superficial and advanced stage

bladder cancer. ONKOLOGIE, 18: 202-210 IF: 0,462, anteiliger IF: 0,07702

13. Rhomberg W, Schmoll HJ, Schneider B: (1995) High frequency of metalworkers

among patients with seminomatous tumors of the testis: a case-control study. AM J

IND MED, 28: 79-87. 7573077 IF: 0,987, anteiliger IF: 0,32907

14. Thiel I, Schmoll HJ, Bokemeyer C: (1995) Primary osteogenic sarcoma of the breast:

Report of a case and a short review of the literature. ONKOLOGIE, 18: 357-361 IF: 0,462, anteiliger IF: 0,15403


Originalarbeiten

1. Andrews PW, Casper J, Damjanov I, Duggan-Keen M, Giwercman A, Hata JI, von Keitz

A, Looijenga LHJ, Millan JL, Oosterhuis JW, Pera M, Sawada M, Schmoll HJ,

Skakkebaek NE, van Putten W, Stern P: (1996) Comparative analysis of cell surface

antigens expressed by cell lines derived from human germ cell tumors. INT J CANCER,

66: 806-816 IF: 3,534, anteiliger IF: 0,08416

2. Berger C, Bokemeyer C, Schuppert F, Schmoll HJ: (1996) Endocrinological late effects

after chemotherapy for testicular cancer. BRIT J CANCER, 73: 1108-1114 IF: 3,666, anteiliger IF: 1,22188

3. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W: (1996) Hochdosischemotherapie bei

Hodentumoren. ONKOLOGE, 2: 28-32 IF: 0, anteiliger IF: 0

4. Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Diehl A, Bokemeyer C,

Schmoll HJ, Nichols CR, Einhorn LH, Siegert W: (1996) High-dose chemotherapy as

salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables.

J CLIN ONCOL, 14: 2638-2645 IF: 7,881, anteiliger IF: 0,26275

5. Beyer J, Kramer A, Mandanas R, Linkesch W, Greinix A, Droz JP, Culine S, Diehl A,

Bokemeyer C, Schmoll HJ, Einhorn LH, Nichols CR, Siegert W: (1996) Treatment

outcome of high-dose chemotherapy as salvage treatment in male germ cell tumors:

a multivariate analysis of prognostic factors. J CLIN ONCOL, 14: 2638-2645 IF: 7,881, anteiliger IF: 0,23887

6. Bokemeyer C, Beyer J, Metzner B, Rüther U, Weißbach L, Köhrmann U, Verbeek W,

Harstrick A, Schmoll HJ: (1996) Phase II study of paclitaxel in patients with relapsed or

cisplatin-refractory cancer. ANN ONCOL, 7: 31-34 IF: 2,736, anteiliger IF: 0,91191

7. Bokemeyer C, Fels LM, Dunn TA, Voigt W, Gaedeke J, Schmoll HJ, Stolte H: (1996)

Silibinin protects against cisplatin-induced nephrotoxicity without compromising

cisplatin or ifosfamide antitumor activity. BRIT J CANCER, 74: 2036-2041 IF: 3,666, anteiliger IF: 0,24445

8. Bokemeyer C, Köhrmann O, Tischler J, Weißbach L, Räth U, Haupt A, Schöffski P,

Schmoll HJ: (1996) A randomized trial of cisplatin, etoposide and bleomycin (PEB)

versus carboplatin, etoposide and bleomycin (CEB) for patients with good risk

metastatic non-seminomatous germ cell tumors. ANN ONCOL, 7: 1015-1022 IF: 2,736, anteiliger IF: 0,91191

9. Bokemeyer C, Kuczyk MA, Dunn TA, Serth T, Hartmann K, Jonasson J, Jonas U,

Schmoll HJ: (1996) Expression of stem cell factor and its receptor c-kit protein in

normal testicular tissue and malignant germ-cell tumors. J CANCER RES CLIN, 122:

301-306 IF: 1,093, anteiliger IF: 0,3643

10. Bokemeyer C, Kuczyk MA, Köhne CH, Einsele H, Kynast B, Schmoll HJ: (1996)

Hematopoetic growths factors and treatment of testicular cancer: Biological

interactions routine use and dose-intensive chemotherapy. ANN HEMATOL, 72: 1-9 IF: 1,206, anteiliger IF: 0,40196

11. Bokemeyer C, Kuczyk MA, Köhne H, Einsele H, Kynast B, Schmoll HJ: (1996)

Treatment of testicular cancer and hematopoietic growth factors: Biological

interactions routine use and dose-intensive chemotherapy. ANN HEMATOL, 7: 1-9 IF: 1,206, anteiliger IF: 0,40196

12. Bokemeyer C, Kuczyk MA, Köhne H, Haupt A, Schmoll HJ: (1996) Das Risiko

sekundärer Neoplasien nach Behandlung maligner Keimzelltumoren des Hodens.

MED KLIN-INTENSIVMED, 91: 703-710 IF: 0, anteiliger IF: 0

13. Bokemeyer C, Kuczyk MA, Serth, Hartmann JT, Schmoll HJ, Jonas U, Kanz L: (1996)

Treatment of clinical stage I testicular cancer and a possible role for new biological

prognostic parameters. J CANCER RES CLIN, 122: 575-584 IF: 1,093, anteiliger IF: 0,07288

14. Bokemyer C, Berger C, Kuczyk MA, Schmoll HJ: (1996) Evaluation of long-term toxicity

after chemotherapy for testicular cancer. J CLIN ONCOL, 14: 2923-2932 IF: 7,881, anteiliger IF: 2,62674

15. Borchard E, Engelhardt, Frommhold, Hartung, Hermanek, Herrmann, Hossfeld,

Junginger, Kirchner, Kreuser, Meyer, Müller, Pichlmaier, Queißer, Schlag, Schmoll,

Stock, Wilke: (1996) Konsens der CAO, AOI und ARO zur Diagnostik und Therapie des

primären Magenlymphoms. ONKOLOGIE, 19: 360-363 IF: 0,451, anteiliger IF: 0,0094

16. Dunn TA, Schmoll HJ, Grünwald V, Bokemeyer C, Casper J: (1996) Amifostine does not

alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer.

ANTI-CANCER DRUG, 7: 1-5 IF: 1,397, anteiliger IF: 0,15525

17. Erlichman C, Fine S, Kerr I, Hoffmann W, Görg C, Schmoll HJ, Preusser P, Thuerlimann

B, Gustavsson B: (1996) A phase II trial of 5-fluorouracil and 1-leucovorin in patients

with metastatic colorectal cancer. AM J CLIN ONCOL-CANC, 19: 26-31 IF: 0,921, anteiliger IF: 0,04387

18. Fels LM, Bokemeyer C, van Rhee J, Schmoll HJ, Stolte H: (1996) Evaluation of late

nephrotoxicity in long-term survivors of Hodgkin's disease. ONCOLOGY-BASEL, 53:

73-78 IF: 2,097, anteiliger IF: 0,23305

19. Hartmann JT, Thiel I, Schmoll HJ, Einsele H, Kanz L, Bokemeyer C: (1996) Malignant

fibrous histiocytoma of bone - review of thirteen cases. ONCOL REP, 3: 1-5 IF: 0,476, anteiliger IF: 0,03967

20. Rambusch EG, Schuppert F, Müller-Kunert E, Stöcker W, Bokemeyer C, Schmoll HJ,

von zur Mühlen A: (1996) Zytokintherapie und Endokrinium: Ist es sinnvoll, mehr als

die Schilddrüse zu untersuchen? MED KLIN-INTENSIVMED, 91: 59-65 IF: 0, anteiliger IF: 0

21. Rüther U, Nunnensiek C, Sessler R, Stilz S, Ulshöfer T, Müller HAG, Bader H,

Bokemeyer C, Schmoll HJ, Toomes H, Jipp P: (1996) Efficacy of antiestrogen

treatment in a benign metastasizing leimyoma with paraneoplastic estradiol

production. ONCOL REP, 3: 293-299 IF: 0,476, anteiliger IF: 0,01763

22. Schmoll HJ: (1996) Die Therapie von Keimzelltumoren: Modell für eine

interdisziplinäre Behandlungsstrategie. MED KLIN-INTENSIVMED, 3: 80-84 IF: 0, anteiliger IF: 0

23. Schmoll HJ: (1996) Development of Treatment for Advanced Colorectal Cancer:

Infusional 5-FU and the role of new agents. EUR J CANCER, 32: S18-22 IF: 2,017, anteiliger IF: 2,017

24. Schmoll HJ, Bokemeyer C: (1996) Sequential intermediate high-dose chemotherapy in

the primary treatment of poor risk testicular cancer. BONE MARROW TRANSPL, 18:

48-49 IF: 2,771, anteiliger IF: 1,3855


Originalarbeiten

1. Bamberg M, Schmoll HJ, Weißbach L, Beyer J, Bokemeyer C, Harstrick A, Höltl W,

Souchon R, Vogler H: (1997) An interdiciplinary consensus conference on the

diagnosis and therapy of testicular tumors. STRAHLENTHER ONKOL, 173: 397-406 IF: 0, anteiliger IF: 0

2. Berkovic D, Grundel O, Berkovic K, Wildfang I, Hess CF, Schmoll HJ: (1997) Synergistic

cytotoxic effects of either phospholipid analogues and ionizing radiation in human

carcinoma cells. RADIOTHER ONCOL, 43: 293-301 IF: 1,924, anteiliger IF: 0,64127

3. Bokemeyer C, Franzke A, Hartmann JT, Schöber C, Arseniev L, Metzner B, Link H, Kanz

L, Schmoll HJ: (1997) A Phase I/ II Study of Sequential, Dose-Escalated, High-Dose

Ifosfamide plus Doxorubicin with Peripheral Blood Stem Cell Support for the

Treatment of Patients with Advanced Soft Tissue Sarcomas. CANCER-AM CANCER

SOC, 6: 1221-1227 IF: 3,296, anteiliger IF: 1,09856

4. Bokemeyer C, Nowak P, Haupt A, Metzner B, Köhne H, Hartmann JT, Kanz L, Schmoll

HJ: (1997) Treatment of brain metastases in patients with testicular cancer. J CLIN

ONCOL, 15: 1449-1454 IF: 7,878, anteiliger IF: 2,62574

5. Dunn TA, Schmoll HJ, Grünewald V, Bokemeyer C, Casper J: (1997) Comparative

cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell

lines. INVEST NEW DRUG, 15: 109-114 IF: 0,543, anteiliger IF: 0,06035

6. Dunn T, Schmoll HJ, Grünewald V, Casper J, Bokemeyer C: (1997) Pre-clinical activity

of taxol in nonseminomatous germ cell tumor cell lines and nude mouse xenografts.

INVEST NEW DRUG, 15: 91-98 IF: 0,543, anteiliger IF: 0,06035

7. Harstrick A, Köhne CH, Hiddemann W, Preusser P, Berns T, Seeber S, Wilke H, Schmoll

HJ: (1997) Modulation of 5-Flourouracil with Metotrexate and Low-dose N-

(phosphonacety)-L-aspartete (PALA) in inactive advanced pancreatic carcinoma. ANN


8. Hartmann JT, Candelaria M, Kuczyk MA, Schmoll HJ, Bokemeyer C: (1997)

Comparison of histological results from the resection of residual masses at different

sites after chemotherapy for metastatic non-seminomatous germ cell tumors. EUR J

CANCER, 33: 843-847 IF: 2,407, anteiliger IF: 0,2675

9. Hartmann JT, Schmoll HJ, Kuczyk MA, Candelaria M, Bokemeyer C: (1997)

Postchemotherapy resections of residual masses from metastatic non-seminomatous

testicular germ cell tumors. ANN ONCOL, 8: 531-538 IF: 2,548, anteiliger IF: 0,28317

10. Hartmannn JT, Schmoll HJ, Thiel I, Kanz L, Bokemeyer C: (1997) Klinische

Verlaufsbeobachtung von Patienten mit malignem fibrösen Histiozytom des

Knochens und Übersicht zur chemotherapeutischen Behandlung. TUMORDIAGN

THER, 1: Jan 34 IF: 0,148, anteiliger IF: 0,01645

11. Hartmann, Schmoll E, Bokemeyer C, Fety, Lucas, D´Agay, Schmoll HJ: (1997) Hepatic

arterial infusion of the nitrosourea derivate fotemustine for the treatment of liver

metastases from colorectal carcinoma. ONCOL REP, 4: 167-172 IF: 0,407, anteiliger IF: 0,13565

12. Köhne C, Harstrick A, Hiddemann W, Schöffski P, Wilke H, Bokemeyer C, Dörken B,

Schmoll HJ: (1997) Modulation of 5-Flourouracil with Metotrexate and Low-dose N-

(phosphonacety)-L-aspartete in Patients with Advanced Colorectal Cancer. Results of

a Phase II Study. EUR J CANCER, 33: 1896-1899 IF: 2,407, anteiliger IF: 0,80225

13. Köhne C, Wilke H, Hiddemann W, Bokemeyer C, Lohrmann HP, Bodenstein H, Preiss J,

Rauschecker H, Hill H, Käufer C, Fischer JT, Ohl U, Urbanitz D, Balleisen L, Schmoll HJ:

(1997) Phase II Evaluation of 5-Flourouracil plus Folinic acid and alpha 2b-interferon

in metastatic colorectal cancer. ONCOLOGY-BASEL, 54: 98-101 IF: 2,141, anteiliger IF: 0,7136

14. Malek NP, Casper J, Looijenga LH, Strohmeyer T, Schmoll HJ, Nordheim A, Janknecht

R: (1997) Quantification of additional short arms of chromosome 12 in germ cell

tumors using the polymerase chain reaction. EUR J CANCER, 33: 1488-1494 IF: 2,407, anteiliger IF: 0,1605

15. Schmoll HJ: (1997) Prognostic factors for advanced seminoma - a solid basis for

clinical trials (Editorial). EUR J CANCER, 9: 1347-1350 IF: 2,407, anteiliger IF: 2,407

16. Schmoll HJ, Bamberg M, Weißbach L: (1997) Interdisziplinäre Konsensus-Konferenz

zur Diagnostik und Therapie von Hodentumoren. ONKOLOGIE, 20: 164-170 IF: 0,328, anteiliger IF: 0,10932

17. Schmoll HJ, Büchele T, Schöber C: (1997) The role of second line chemotherapy in

colorectal cancer. ONKOLOGIE, 20: 288-294 IF: 0,328, anteiliger IF: 0,10932

18. Schöber C, Galanski M, Jörgensen M, Schmoll HJ: (1997) Management of endocrine

pancreatic tumors. WIEN KLIN WOCHENSCHR, 147: 18-23 IF: 0,411, anteiliger IF: 0,13699

19. Seliger B, Dunn T, Schwenzer A, Casper J, Huber C, Schmoll HJ: (1997) Analysis of the

MHC-Class I antigen presentation machinery in a human embryonal carcinoma cell

line: evidence for suppression of TAP, LMP and MHC class I expression. SCAND J

IMMUNOL, 46: 625-632 IF: 1,749, anteiliger IF: 0,58294

20. Weißbach L, Bamberg M, Schmoll HJ: (1997) Interdisciplinary consensus conference

on diagnosis and therapy of testicular cancer. UROLOGE, 36: 362-368



Originalarbeiten

1. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W: (1998) Salvagetherapie rezidivierter

und refraktärer Hodentumoren. ONKOLOGE, 4: 541-546 IF: 0, anteiliger IF: 0

2. Beyer J, Schmoll HJ: (1998) Prognosefaktoren bei metastasierten seminomatösen und

nichtseminomatösen Hodentumoren. ONKOLOGE, 4: 518-523 IF: 0, anteiliger IF: 0

3. Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA,

Kanz L: (1998) Analysis of risk factors for cisplatin-induced ototoxicity in patients with

testicular cancer. BRIT J CANCER, 77: 1355-1362 IF: 3,036, anteiliger IF: 0,20244

4. Bokemeyer C, Gerl A, Harstrick A, Schmoll HJ: (1998) Therapie des fortgeschrittenen

nichtseminomatösen Keimzelltumors. ONKOLOGE, 4: 532-540 IF: 0, anteiliger IF: 0

5. Bokemeyer T, Harstrick A, Beyer J, Metzner B, Rüther U, Hartmann JT, Holstein K,

Derigs HG, de Wit R, Casper J, Schöffski P, Kuhrer I, Illiger HJ, Kempf B, Reichle A,

Foller A, Hossfeld DK, Fischer JT, Berdel WE, Gerhartz HH, Kirchner H, Pflüger KH,

Ostermann H, Kanz L, Schmoll HJ: (1998) The use of dose-intensified chemotherapy in

the treatment of metastatic non-seminomatous testicular germ cell tumors. German

Testicular Cancer Study Group. SEMIN ONCOL, 25: 24-32 IF: 2,252, anteiliger IF: 0,75059

6. Dunn T, Schmoll HJ, Rie C, Hartmann K, Casper J: (1998) Production and pre-clinical

significance of hematopoietic peptide growth factor (HPGF) in human non-

seminomatous germ cell tumor (NSGCT) cell lines. J CANCER RES CLIN, 124: 435-443 IF: 1,183, anteiliger IF: 0,13147

7. Hartmann JT, Köhne CH, Schmoll HJ, Daikeler T, Kanz L, Bokemeyer C: (1998) Is

continuous 24-hour infusion of 5-Flourouracil plus high-dose folinic acid effective in

patients with progressive or recurrent colorectal cancer? A phase II Study.

ONCOLOGY-BASEL, 55: 320-325 IF: 2,858, anteiliger IF: 0,23821

8. Hartmann JT, Schmoll E, Bokemeyer C, Fety R, Lucas C, Giroux B, Schmoll HJ: (1998)

Phase I Pharmacological Study of Intra-arterially Infused Fotemustine for Colorectal

Liver Metastases. EUR J CANCER, 34: 87-91 IF: 2,743, anteiliger IF: 0,91424

9. Köhne CH, Schöffski P, Wilke H, Kaufer C, Andreesen R, Ohl U, Klaasen U,

Westerhausen M, Hiddemann W, Schott G, Harstrick A, Bade J, Horster A, Schubert

U, Hecker H, Dörken B, Schmoll HJ: (1998) Effective biomodulation by leucovorin of

high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a

randomized trial in patients with advanced colorectal cancer. J CLIN ONCOL, 16: 418-

426 IF: 8,228, anteiliger IF: 2,74239

10. Kollmannsberger C, Beyer J, Droz JP, Harstrick A, Hartmann JT, Biron P, Flechon A,

Schöffski P, Kuczyk M, Schmoll HJ, Kanz L, Bokemeyer C: (1998) Secondary leukemia

following high cumulative doses for Etoposide in Patients treated for advanced germ

cell tumors. J CLIN ONCOL, 16: 3386-3391 IF: 8,228, anteiliger IF: 0,27432

11. Korfel A, Scheulen ME, Schmoll HJ, Gründel O, Harstrick A, Knoche M, Fels LM,

Skorzec M, Bach F, Baumgart J, Saß G, Seeber S, Thiel E, Berdel WE: (1998) Phase I

Clinical and Pharmacokinetic Study of Titanocene Dichloride in adults with advanced

solid tumors. CLIN CANCER RES, 4: 2701-2708 IF: 2,941, anteiliger IF: 0,08171

12. Schmoll HJ: (1998) Is there a standard adjuvant treatment for colon cancer?

(Editorial). EUR J CANCER, 34: 1659-1663 IF: 2,743, anteiliger IF: 2,743

13. Schmoll HJ: (1998) Is there a standard adjuvant treatment for rectal cancer?

(Editorial). EUR J CANCER, 34: 1827-1835 IF: 2,743, anteiliger IF: 2,743

14. Schmoll HJ, Beyer J: (1998) Prognostic factors in metastatic germ cell tumors. SEMIN


15. Schmoll HJ, Weißbach L, Bamberg M: (1998) Editorial: Therapie des Hodentumors:

das Zauberwort heißt Interdisziplinarität. ONKOLOGE, 4: 471-472 IF: 0, anteiliger IF: 0


Originalarbeiten

1. Bokemeyer C, Gerl A, Schöffski P, Harstrick A, Niederle N, Beyer J, Casper J, Schmoll

HJ: (1999) Gemcitabine in patients with relapsed or Cisplatin-refractory testicular

cancer. J CLIN ONCOL, 17: 512-516 IF: 7,963, anteiliger IF: 2,65407

2. Bokemeyer C, Kollmannsberger C, Harstrick A, Beyer J, Gerl A, Casper J, Metzner B,

Hartmann JT, Schmoll HJ, Kanz L: (1999) Treatment of patients with Cisplatin-

refractory testicular germ-cell cancer. INT J CANCER, 83: 848-851 IF: 3,545, anteiliger IF: 0,14774

3. Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B,

Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C: (1999) First-Line High-Dose

Chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with

advanced germ cell tumors: A multivariate and matched-pair analysis. J CLIN ONCOL,

17: 3450-3456 IF: 7,963, anteiliger IF: 0,29498

4. Dempke W, Behrmann C, Schöber C, Büchele T, Grothey A, Schmoll HJ: (1999)

Diagnostisches und therapeutisches Management der oberen Einflussstauung. MED

KLIN-INTENSIVMED, 94: 681-684 IF: 0, anteiliger IF: 0

5. Dempke W, Büchele T, Wolf HH, Grothey A, Schmoll HJ: (1999) Diagnostik und

Therapie maligner Pleura- und Perikardergüsse. ONKOLOGIE, 22: 526-529 IF: 0,382, anteiliger IF: 0,12732

6. Dempke W, Voigt W, Grothey A, Schmoll HJ: (1999) Preferential repair of the N-ras

gene in K562 cells after exposure to cisplatin. ANTI-CANCER DRUG, 10: 545-549 IF: 1,594, anteiliger IF: 0,53128

7. Fossa SD, Bokemeyer C, Gerl A, Culine S, Jones WG, Mrad GM, Germa-Luch JR, Pont J,

Schmoll HJ, Tjulandin S: (1999) Treatment outcome of patients with brain metastases

from malignant germ cell tumors. CANCER-AM CANCER SOC, 85: 988-997 IF: 3,632, anteiliger IF: 0,15136

8. Grothey A, Voigt W, Schöber C, Müller T, Dempke W, Schmoll HJ: (1999) The role of

insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis,

and chemoresistance in solid tumors. J CANCER RES CLIN, 125: 166-173 IF: 1,052, anteiliger IF: 0,35063

9. Hartmann JT, Albrecht C, Schmoll HJ, Kuczyk MA, Kollmannsberger C, Bokemeyer C:

(1999) Long-term effects on sexual function and fertility after treatment of testicular

cancer. BRIT J CANCER, 80: 801-807 IF: 3,282, anteiliger IF: 0,27355

10. Kellner O, Dempke W, Schmoll HJ: (1999) Glukose-Infusionen - eine mögliche

effektive Therapieoption bei der Ifosfamid-induzierten Enzephalopathie. DEUT MED

WOCHENSCHR, 124: 1086-1087 IF: 0,684, anteiliger IF: 0,22798

11. Schmoll HJ: (1999) Standards in der Behandlung kolorektaler Karzinome - Wunsch

und Wirklichkeit. ONCOLOGY-BASEL, 99: 6-7 IF: 2,684, anteiliger IF: 2,684

12. Schmoll HJ: (1999) Treatment of testicular tumours based on risk factors. CURR OPIN

UROL, 9: 431-438 IF: 0, anteiliger IF: 0

13. Schmoll HJ, Büchele T, Grothey A, Dempke W: (1999) Where do we stand with 5-FU?

SEMIN ONCOL, 26: 589-605



Originalarbeiten

1. Brieger P, Marneros A, Wolf HH, Schmoll HJ: (2000) Manic episode in an ifosfamide-

treated patient. GEN HOSP PSYCHIAT, 22: 52-3 10766557 IF: 1,512, anteiliger IF: 0,25205

2. Büchele T, Grothey A, Schmoll HJ: (2000) Neue Perspektiven mit neuen Zytostatika in

der Behandlung des kolorektalen Karzinoms. ONKOLOGE, 6: 410-419 IF: 0, anteiliger IF: 0

3. Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ: (2000) Cisplatin resistance and

oncogenes - a review. ANTI-CANCER DRUG, 11: 225-236 IF: 1,57, anteiliger IF: 0,52328

4. Dempke W, von Poblozki A, Grothey A, Schmoll HJ: (2000) Human hematopoietic

growth factors: old lessons and new perspectives. ANTICANCER RES, 20: 5155-5164 IF: 1,331, anteiliger IF: 0,44362

5. Grothey A, Kegel T, Dempke W, Schmoll HJ: (2000) Systemische Therapie des

hepatozellulären Karzinoms. ONKOLOGE, 6: 327-335 IF: 0, anteiliger IF: 0

6. Kellner O, Voigt W, Schneyer U, Dempke W, Schmoll HJ: (2000) HCG-induced

hyperthyreosis in germ cell cancer. ANTICANCER RES, 20: 5135-8 IF: 1,331, anteiliger IF: 0,44362

7. Kollmannsberger C, Nichols C, Bamberg M, Hartmann JT, Schleucher N, Beyer J,

Schöffski P, Gerigs G, Rüther U, Bohlke I, Schmoll HJ, Kanz L, Bokemeyer C: (2000)

First-Line High-Dose chemotherapy + radiation therapy in patients with metastatic

germ-cell cancer and brain metastases. ANN ONCOL, 11: 553-559 IF: 3,249, anteiliger IF: 0,09847

8. Schmiegel W, Adler G, Frühmorgen P, Fölsch U, Greaven U, Layer P, Petrasch S,

Porschen R, Pox C, Sauerbruch T, Schmoll HJ, Zeitz M: (2000) Kolorektales Karzinom:

Prävention und Früherkennung in der asymptomatischen Bevölkerung - Vorsorge bei

Risikopatienten - Endoskopische Diagnostik, Therapie und Nachsorge von Polypen

und Karzinomen. Z GASTROENTEROL, 38: 49-75 IF: 0,887, anteiliger IF: 0,02957

9. Schmoll HJ: (2000) Aktive spezifische Immunotherapie (ASI) beim Kolonkarzinom.

STRAHLENTHER ONKOL, 176: 47-48 IF: 2,846, anteiliger IF: 2,846

10. Schmoll HJ, Krege S, Souchon R: (2000) Interdisziplinärer Konsensus zur Diagnostik

und Therapie von Hodentumoren: Ergebnisse einer Update-Konferenz auf der

Grundlage evidenzbasierter Medizin. ONKOLOGIE, 23: 603-613 IF: 0,64, anteiliger IF: 0,21331

11. Schneider I, Rettkowski O, Markau S, Wolf HH, Deuber HJ, Schmoll HJ, Osten B:

(2000) Erfassung der Nierenschädigung beim Plasmozytom durch die Cystatin C-

Bestimmung im Serum. LABORATORIUMSMEDIZIN, 24: 1900 IF: 0, anteiliger IF: 0

12. Souchon R, Krege S, Schmoll HJ, Albers P, Veyer J, Bokemeyer C, Claßena J,

Dieckmann KP, Hartmann M, Heidenreich A, Höltl W, Kliesch S, Köhrmann KU, Kuczyk

M, Schmidberger H, Weinknecht S, Winter E, Wittekind C, Bamberg M: (2000)

Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren.

STRAHLENTHER ONKOL, 176: 388-405 IF: 2,846, anteiliger IF: 0,05582

13. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M,

Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B,

Couvreur ML, Baron B, Wils JA: (2000) Final results of a randomized phase II trial of

sequential high-dose methotrexate, flourouracil, and doxorubin versus etoposide,

leucovorin and flourouracil versus infusion fluorouracil and cisplatin in advanced

gastric cancer: a trial of the European Organisation for Research and Treatment of

Cancer Gastrointestinal Tract Cancer Cooperative Group. J CLIN ONCOL, 18: 2648-

2657 IF: 8,773, anteiliger IF: 0,19499

14. Voigt W, Bulankin A, Müller T, Schöber C, Grothey A, Hoang-Vu C, Schmoll HJ: (2000)

Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic

thyroid cancer cell lines. CLIN CANCER RES, 6: 2087-2093 IF: 4,643, anteiliger IF: 1,54751

15. von Poblozki A, Dempke W, Schmoll HJ: (2000) Carboxypeptidase-G2-Rescue bei

einer Patientin mit Methotrexat-induziertem Nierenversagen. MED KLIN-

INTENSIVMED, 95: 457-460 IF: 0, anteiliger IF: 0


Originalarbeiten

1. Bokemeyer C, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Schmoll HJ, Kanz

L, Einhorn L, Nichols CR, Hartmann JT: (2001) Extragonadal seminoma: an

international multicenter analysis of prognostic factors and long term treatment

outcome. CANCER-AM CANCER SOC, 91: 1394-1401 IF: 3,909, anteiliger IF: 0,13033

2. Dempke W, Rie C, Grothey A, Schmoll HJ: (2001) Cyclooxygenase-2: a novel target for

cancer chemotherapy? J CANCER RES CLIN, 127: 411-417 IF: 2,194, anteiliger IF: 0,73126

3. Dempke W, Schmoll HJ: (2001) Mögliche neue Indikationen für die Therapie mit

Erythropetin. MED KLIN-INTENSIVMED, 96: 467-474 IF: 0, anteiliger IF: 0

4. Dempke W, von Poblozki A, Kellner O, Wolf HH, Schmoll HJ: (2001) Hämorrhagische

Diathese als Erstsymptom eines Magenkarzinoms. WIEN KLIN WOCHENSCHR, 112:

1053-1058 IF: 0,646, anteiliger IF: 0,21531

5. Fittkau M, Gerlach R, Schmoll HJ: (2001) Protective effect of oral phosphatidylcholine

on radiation-induced release of intestinal peptidases in rats. J CANCER RES CLIN, 127:

444 IF: 2,194, anteiliger IF: 0,73126

6. Fittkau M, Grothey A, Gerlach R, Schmoll HJ: (2001) A low dose of ionizing radiation

increases luminal release of intestinal peptidases in rats. J CANCER RES CLIN, 127: 96-

100 IF: 2,194, anteiliger IF: 0,73126

7. Fizazi K, Tjulandin S, Salvioni R, Germa-Luch JR, Bouzy J, Ragan D, Bokemeyer C, Gerl

A, Flechon A, de Bono JS, Stenning S, Horwich A, Pont J, Albers P, De Giorgi U, Bower

M, Bulanov A, Pizzocaro G, Aparicio J, Nichols CR, Theodore C, Hartmann JT, Schmoll

HJ, Kaye SB, Culine S, Droz JP, Mahe C: (2001) Viable malignant cells after primary

Chemotherapy for disseminated nonseminomatous germ cell tumors: Prognostic

factors and role of postsurgery chemotherapy - results from an international study

group. J CLIN ONCOL, 19: 2647-2657 IF: 8,53, anteiliger IF: 0,11376

8. Grothey A, Schmoll HJ: (2001) New Chemotherapy approaches in colorectal cancer.

CURR OPIN ONCOL, 13: 275-286 IF: 0, anteiliger IF: 0

9. Hartmann JT, Einhorn L, Nichols CR, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J,

Pont J, Schmoll HJ, Kanz L, Bokemeyer C: (2001) Second-line chemotherapy in

patients with released extragonadal nonseminomatous germ cell tumors: Results of

an international multicenter analysis. J CLIN ONCOL, 19: 1641-1648 IF: 8,53, anteiliger IF: 0,28439

10. Hoff PM, Cassidy J, Schmoll HJ: (2001) The evolution of Fluoropyrimidine Therapy:

From Intravenous to Oral. ONCOLOGIST, 6: 3-11 IF: 0, anteiliger IF: 0

11. Kellner O, Krüger W, Schmoll HJ: (2001) Standardmanagement von Fieber unklarer

Genese (FUO) bei hämatologischen oder onkologischen Patienten in der

Neutropenie. PHARMAZIE, 3: 03. Apr IF: 0,498, anteiliger IF: 0,16598

12. Krege S, Souchon R, Schmoll HJ: (2001) Interdisciplinary consensus on Diagnosis and

Treatment of Testicular Germ Cell Tumors: Result of an Update Conference on

Evidence-Based Medicine (EBM). EUR UROL, 40: 372-391


13. Krege S, Souchon R, Schmoll HJ: (2001) Interdisziplinärer Konsensus zur Diagnostik

und Therapie von Hodentumoren. Ergebnisse einer Update-Konferenz auf Grundlage

evidensbasierter Medizin. UROLOGE, 2: 137-147 IF: 0,497, anteiliger IF: 0,16565

14. Rades D, Kühnel G, Wildfang I, Bömer AR, Schmoll HJ, Knapp W, Karstens JH: (2001)

Localised disease in cancer of unknown primary (CUP): the value of positron emission

tomography (PET) for individual therapeutic management. ANN ONCOL, 12: 1605-

1609 IF: 3,153, anteiliger IF: 0,21024

15. Rick O, Bokemeyer C, Beyer J, Hartmann JT, Schwella N, Kingreen D, Neureither S,

Metzner B, Casper J, Wandt H, Hartmann F, Schmoll HJ, Derigs G, Gerl A, Berdel W,

Kanz L, Siegert W: (2001) Salvage treatment with paclitaxel, ifosfamide and cisplatin

(TIP) plus high-dose carboplatin, etoposide and thiotepa (CET) followed by

autologous stem cell rescue in patients with relapsed or refractory germ cell cancer. J

CLIN ONCOL, 19: 81-88 IF: 8,53, anteiliger IF: 0,18959

16. Schmoll HJ: (2001) Kolorektale Karzinome. ONKOLOGIE, 24: 1-8 IF: 0,573, anteiliger IF: 0,573

17. Schmoll HJ, Cassidy J: (2001) Integrating Oxaliplatin into the Management of

Colorectal Cancer. ONCOLOGIST, 6: 24-28 IF: 0, anteiliger IF: 0

18. Wolf HH, Förster W, Schöber C, Grothey A, Dempke W, Schmoll HJ: (2001)

Cyclooxigenase-2-inhibitors in colon cancer. ONKOLOGIE, ?: # IF: 0,573, anteiliger IF: 0,19098


Originalarbeiten

1. Bokemeyer C, Nichols CR, Droz JP, Schmoll HJ, Horwich A, Gerl A, Fossa SD, Beyer J,

Pont J, Kanz L, Einhorn L, Hartmann JT: (2002) Extragonadal germ cell tumors of the

mediastinum and retroperitoneum: results from an international analysis. J CLIN

ONCOL, 20: 1864-73. 11919246 IF: 9,868, anteiliger IF: 0,329

2. Fittkau M, Gerlach R, Schmoll HJ: (2002) Phosphatidylcholine does not protect rats

against 5-fluorouracil/ folinic acid-induced damage of the intestinal luminal mucosa. J

CANCER RES CLIN, 128: 80-84 IF: 2,197, anteiliger IF: 0,73226

3. Grothey A, Kellermann L, Schmoll HJ: (2002) [Deficits in management of patients with

colorectal carcinoma in Germany. Results of multicenter documentation of therapy

algorithms]. MED KLIN-INTENSIVMED, 97: 270-7. 12078387 IF: 0, anteiliger IF: 0

4. Krüger WH, Wolf HH, Voigt W, Skibbe T, Schmoll HJ: (2002) Detection of an occult B-

cell lymphoma in the donor's bone marrow prior to HLA-matched sibling

transplantation. J HEMATOTH STEM CELL, 11: 169-70 11983090 IF: 1,628, anteiliger IF: 0,54261

5. Mantovani L, Hasenclever D, Krahl R, Ponisch W, Herold M, Pasold R, Fiedler F,

Dolken G, Kampfe D, Schmoll HJ, Subert R, Kubel M, Niederwieser D, Helbig W:

(2002) Intermediate-dose cytarabine treatment delivered at moderate infusion rates

for de novo acute myeloid leukemia-results of a phase I-II study. LEUKEMIA

LYMPHOMA, 43: 265-74. 11999557 IF: 1,335, anteiliger IF: 0,03709

6. Schmoll HJ: (2002) Extragonadal germ cell tumors. ANN ONCOL, 13: 265-

72. 12401700 IF: 3,114, anteiliger IF: 3,114

7. Schmoll HJ: (2002) The role of oxaliplatin in the treatment of advanced metastatic

colorectal cancer: prospects and future directions. SEMIN ONCOL, 29(5 Suppl 15): 34-

9. 12422306 IF: 3,5, anteiliger IF: 3,5

8. Schmoll HJ: (2002) Is there a role of high-dose chemotherapy in lymphoma and solid

tumours: The present state of the art. CRIT REV ONCOL HEMAT, 41: 127-128 IF: 2,758, anteiliger IF: 2,758

9. Van Cutsem E, Dicato M, Wils J, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D,

Johnston P, Kerr D, Koehne CH, Labianca R, Minsky B, Nordlinger B, Roth A, Rougier P,

Schmoll HJ: (2002) Adjuvant treatment of colorectal cancer (current expert opinion

derived from the Third International Conference: Perspectives in Colorectal Cancer,

Dublin, 2001). EUR J CANCER, 38: 1429-36. 12110487 IF: 3,562, anteiliger IF: 1,18721

10. Voigt W, Behrmann C, Schlüter A, Bläser F, Wunderlich D, Harba A, Kegel T, Grothey

A, Schmoll E, Schmoll HJ: (2002) Hepatic transcatheter arterial chemoembolisation in

refractory liver metastasis of colorectal cancer with Mitomycin C, Interferon-

ALPHA2b and Dexamethasone mixed with Amilomer DSM 45/25 (Sperex®) followed

by Oxaliplatin, Folinic acid and 5-Fluorouracil - feasibility and preliminary results.

ONKOLOGIE, 25: 158-164 IF: 0,855, anteiliger IF: 0,28497

11. Voigt W, Behrmann C, Schlueter A, Kegel T, Grothey A, Schmoll HJ: (2002) A new

chemoembolization protocol in refractory liver metastasis of colorectal cancer--a

feasibility study. ONKOLOGIE, 25: 158-64. 12006767 IF: 0,855, anteiliger IF: 0,28497


Originalarbeiten

1. Arnold D, Grothey A, Schmoll HJ: (2003) Neue Entwicklungen in der systemischen

Therapie des fortgeschrittenen Kolonkarzinoms. ONKOLOGE, 9: 847-859 IF: 0, anteiliger IF: 0

2. Bokemeyer C, Schleucher N, Metzner B, Thomas M, Rick O, Schmoll HJ,

Kollmannsberger C, Boehlke I, Kanz L, Hartmann JT: (2003) First-line sequential high-

dose VIP chemotherapy with autologous transplantation for patients with primary

mediastinal nonseminomatous germ cell tumours: a prospective trial. BRIT J CANCER,

89: 29-35. 12838296 IF: 3,894, anteiliger IF: 0,16228

3. Kohne CH, Wils J, Lorenz M, Schoffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg

C, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Ruckle H, Lichnitser M,

Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ: (2003) Randomized

phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or

without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal

cancer: European organization of Research and Treatment of Cancer Gastrointestinal

Group Study 40952. J CLIN ONCOL, 21: 3721-8. IF: 10,864, anteiliger IF: 3,62097

4. Kollmannsberger C, Schleucher N, Rick O, Metzner B, Hartmann JT, Schoffski P, Beyer

J, Casper J, Sosada M, Schmoll HJ, Bohlke I, Meisner C, Kanz L, Bokemeyer C: (2003)

Analysis of salvage treatments for germ cell cancer patients who have relapsed after

primary high-dose chemotherapy plus autologous stem cell support. EUR J CANCER,

39: 775-82. 12651203 IF: 3,694, anteiliger IF: 0,10263

5. Mueller T, Voigt W, Simon H, Fruehauf A, Bulankin A, Grothey A, Schmoll HJ: (2003)

Failure of activation of caspase-9 induces a higher threshold for apoptosis and

cisplatin resistance in testicular cancer. CANCER RES, 63: 513-21. 12543810 IF: 8,649, anteiliger IF: 2,88271

6. Paschke R, Kalbitz J, Paetz C, Luckner M, Mueller T, Schmoll HJ, Mueller H, Sorkau E,

Sinn E: (2003) Cholic acid-carboplatin compounds (CarboChAPt) as models for specific

drug delivery: synthesis of novel carboplatin analogous derivatives and comparison of

the cytotoxic properties with corresponding cisplatin compounds. J INORG BIOCHEM,

94: 335-42. 12667704 IF: 2,343, anteiliger IF: 0,11159

7. Paschke R, Paetz C, Mueller T, Schmoll HJ, Mueller H, Sorkau E, Sinn E: (2003)

Biomolecules linked to transition metal complexes-new chances for chemotherapy.

CURR MED CHEM, 10: 2033-44. 12871101 IF: 4,409, anteiliger IF: 0,29399

8. Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R:

(2003) Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J

CLIN ONCOL, 21: 3098-104. 12915600


9. Schmoll HJ: (2003) Dihydropyrimidine dehydrogenase inhibition as a strategy for the

oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal

cancer. ANTI-CANCER DRUG, 14: 695-702. 14551502 IF: 1,938, anteiliger IF: 1,938

10. Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schoffski P,

Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer

C: (2003) Long-term results of first-line sequential high-dose etoposide, ifosfamide,

and cisplatin chemotherapy plus autologous stem cell support for patients with

advanced metastatic germ cell cancer: an extended phase I/II study of the German

Testicular Cancer Study Group. J CLIN ONCOL, 21: 4083-91. IF: 10,864, anteiliger IF: 3,62097


Originalarbeiten

1. Arnold D, Schmoll HJ: (2004) Palliative Systemtherapie beim metastasierten

Ösophaguskarzinom. Sind neue Therapieansätze in Sicht? ONKOLOGE, 10: 1202-1214 IF: 0, anteiliger IF: 0

2. Bokemeyer C, Kollmannsberger C, Stenning S, Hartmann JT, Horwich A, Clemm C,

Gerl A, Meisner C, Ruckerl CP, Schmoll HJ, Kanz L, Oliver T: (2004) Metastatic

seminoma treated with either single agent carboplatin or cisplatin based

combination chemotherapy: a pooled analysis of two randomised trials. BRIT J


3. Fittkau M, Voigt W, Holzhausen HJ, Schmoll HJ: (2004) Saccharic acid 1.4-lactone

protects against CPT-11-induced mucosa damage in rats. J CANCER RES CLIN, 25: 388-

394 15160289 IF: 2,409, anteiliger IF: 0,80292

4. Grothey A, Sargent D, Goldberg RM, Schmoll HJ: (2004) Survival of patients with

advanced colorectal cancer improves with the availability of fluorouracil-leucovorin,

irinotecan, and oxaliplatin in the course of treatment. J CLIN ONCOL, 1: 1209-1214 IF: 9,835, anteiliger IF: 3,27801

5. Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K,

Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB,

Hoelzer D, Ganser A: (2004) Intensive chemotherapy with idarubicin, cytarabine,

etoposide, and G-CSF priming in patiens with advanced myelodysplastic syndrome

and high-risk acute myeloid leukemia. ANN HEMATOL, 83: 498-503 IF: 1,292, anteiliger IF: 0,03077

6. Jordan K, Kellner O, Kegel T, Schmoll HJ, Grothey A: (2004) Phase II Trial of

Capecitabine/ Irinotecan and Capecitabine/ Oxaliplatin in Advanced Colorectal

Cancer. CLIN COLORECTAL CANC, 4: 46-50 IF: 0, anteiliger IF: 0

7. Kegel T, Schmoll HJ: (2004) Systemische Chemotherapie neuroendokriner Tumoren.

ONKOLOGE, 10: 621-633 IF: 0, anteiliger IF: 0

8. Rades D, Fehlauer F, Stalpers LJ, Wildfang I, Zschenker O, Schild SE, Schmoll HJ,

Karstens JH, Alberti W: (2004) A prospective evaluation of two radiotherapy

schedules with 10 versus 20 fractions for the treatment of metastatic spinal cord

compression: final results of a multicenter study. CANCER-AM CANCER SOC, 101:

2687-2692 IF: 1,654, anteiliger IF: 0,07878

9. Schmiegel W, Pox C, Adler G, Fleig W, Fölsch UR, Frühmorgen P, Graeven U,

Hohenberger W, Holstege A, Junginger T, Kühlbacher T, Porschen R, Propping P,

Riemann JF, Sauer R, Sauerbruch T, Schmoll HJ, Zeitz M, Selbmann HK: (2004) S3-

Leitlinienkonferenz "Kolorektales Karzinom". Z GASTROENTEROL, 10: 1129-1177 IF: 1, anteiliger IF: 0,01961

10. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD,

Skakkebaek NE, De Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, De Mulder PH,

Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N,

Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, De Wit

M, Derigs HG, Dieckmann KP, Flasshove M, Garcia Del Muro X, Gerl A, Germa-Lluch

JR, Hartmann M, Heidenreich A, Hoeltl W, Joffe J, Jones W, Kaiser G, Klepp O, Kliesch

S, Kisbenedek L, Koehrmann KU, Kuczyk M, Laguna MP, Leiva O, Loy V, Mason MD,

Mead GM, Mueller RP, Nicolai N, Oosterhof GO, Pottek T, Rick O, Schmidberger H,

Sedlmayer F, Siegert W, Studer U, Tjulandin S, Von der Maase H, Walz P, Weinknecht

S, Weissbach L, Winter E, Wittekind C: (2004) European consensus on diagnosis and

treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus

Group (EGCCCG). ANN ONCOL, 15: 1377-99. 15319245 IF: 4,335, anteiliger IF: 1,44486


Originalarbeiten

1. Arnold D, Schmoll HJ: (2005) (Neo-)adjuvant treatments in colorectal cancer. ANN

ONCOL, 16: ii133-ii140 IF: 4,319, anteiliger IF: 2,1595

2. Diaz-Rubio E, Schmoll HJ: (2005) The future development of bevacizumab in

colorectal cancer. ONCOLOGY-BASEL, 69: 34-45 IF: 1,985, anteiliger IF: 0,9925

3. Diaz-Rubio E, Schmoll HJ: (2005) Introduction. Critical role of anti-angiogenesis and

VEGF inhibition in colorectal cancer. ONCOLOGY-BASEL, 69: 1-3


4. Hochster H, Kettner E, Kroning H, Becker K, Lordick F, Ramanathan RK, Macdonald J,

Hong S, John W, Schmoll HJ: (2005) Phase I/II dose-escalation study of pemetrexed

plus irinotecan in patients with advanced colorectal cancer. CLIN COLORECTAL CANC,

5: 257-262 IF: 0, anteiliger IF: 0

5. Jordan K, Grothey A, Grothe W, Kegel T, Wolf HH, Schmoll HJ: (2005) Successful

treatment of mediastinal lymphomatoid granulomatosis with rituximab

monotherapy. EUR J HAEMATOL, 74: 263-6 15693798 IF: 2,004, anteiliger IF: 0,66793

6. Jordan K, Grothe W, Schmoll HJ: (2005) Paravasation von Zytostatika: Prävention und

Therapie. DEUT MED WOCHENSCHR, 130: 33-37 IF: 0,653, anteiliger IF: 0,21764

7. Jordan K, Grothey A, Kegel T, Fibich C, Schoeber C, Schmoll HJ: (2005) Antiemetic

efficacy of an oral suspension of granisetron plus dexamethasone and influence of

quality of life on risk for nausea and vomiting. ONKOLOGIE, 28: 88-92 IF: 1,206, anteiliger IF: 0,40196

8. Jordan K, Hinke A, Grothey A, Schmoll HJ: (2005) Granisetron versus tropisetron for

prophylaxis of acute chemothrapy-induced emesis: a pooled analysis. SUPPORT CARE


9. Jordan K, Kasper C, Schmoll HJ: (2005) Chemotherapy-induced nausea and vomiting:

current and new standards in the antiemetic prophylaxis and treatment. EUR J


10. Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, Jackisch C, Werner C,

Ziske C, Kirchner H, Metzner B, Souchon R, Ruffert U, Schütt G, Pollmanns A, Schmoll

HJ, Middecke C, Baltzer J, Schrader I, Wiebringhaus H, Ko Y, Rösel S, Schwenzer T,

Wernet P, Hinke A, Bender HG, Frick M, West GSG: (2005) Comparison of rapidly

cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support

versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk

breast cancer: results of a multicentre phase III trial. LANCET, 366: 1935-44 16325695 IF: 23,407, anteiliger IF: 0,31216

11. Pico JL, Rosti G, Kramar A, Wandt H, Kza V, Salvioni R, Theodore C, Lelli G, Siegert W,

Horwich A, Marangolo M, Linkesch W, Pizzocaro G, Schmoll HJ, Bozy J, Droz JP, Biron

P: (2005) A randomised trial of high-dose chemotherapy in the salvage treatment of

patients failing first-line platinum chemotherapy for advanced germ cell tumours.

ANN ONCOL, 16: 1152-1159 IF: 4,319, anteiliger IF: 0,096

12. Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D, Kunstlinger F, Mentha G,

Nordlinger B, Patt Y, Primrose J, Roh M, Rougier P, Ruers T, Schmoll HJ, Valls C,

Vauthey NJ, Cornelis M, Kahan JP: (2005) OncoSurge: a strategy for improving

resectability with curative intent in metastatic colorectal cancer. J CLIN ONCOL, 23:

7125-7134 IF: 11,81, anteiliger IF: 0,23161

13. Rennicke A, Voigt W, Mueller T, Fruehauf A, Schmoll HJ, Beyer C, Dempke W: (2005)

Resistance mechanisms following cisplatin and oxaliplatin treatment of the human

teratocarcinoma cell line 2102EP. ANTICANCER RES, 25: 1147-55 15868958 IF: 1,604, anteiliger IF: 0,10695

14. Schmiegel W, Pox C, Adler G, Fleig W, Folsch UR, Fruhmorgen P, Graeven U,

Hohenberger W, Holstege A, Kuhlbacher T, Proschen R, Propping P, Riemann JF,

Sauer R, Sauberbruch T, Schmoll HJ, Zeitz M, Selbmann He: (2005) S3-guideline

conference "Colorectal Cancer" 2004. DEUT MED WOCHENSCHR, 8; 130 (Suppl. 1):

S5-53 IF: 0,653, anteiliger IF: 0,01361

15. Voigt W, Kegel T, Weiss M, Mueller T, Simon H, Schmoll HJ: (2005) Potential activity

of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J CANCER

RES CLIN, 131: 585-590 IF: 2,503, anteiliger IF: 0,83425


Originalarbeiten

1. Arnold D, Peinert S, Voigt W, Schmoll HJ: (2006) Epidermal growth factor receptor

tyrosine kinase inhibitors: present and future role in gastrointestinal cancer

treatment: a review. ONCOLOGIST, 11: 602-611 IF: 5,206, anteiliger IF: 1,73516

2. Arnold D, Siewczynski R, Schmoll HJ: (2006) The integration of targeted agents into

systemic therapy of metastatic colorectal cancer. ANN ONCOL, 17: x122-x128 IF: 5,179, anteiliger IF: 1,72616

3. Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Schoeffski P, Schmoll H, Van

Cutsem E, Koehne CH: (2006) Does a patient's self-reported health-related quality of

life predict survival beyond key biomedical data in advanced colorectal cancer? EUR J


4. Jordan K, Voigt W, Schmoll HJ: (2006) Chemotherapy induced nausea and vomiting -

a practical treatment approach. DEUT MED WOCHENSCHR, Aug 25; 131 (34-35):

1869-1872 IF: 0,584, anteiliger IF: 0,19465

5. Krege S, Boergermann C, Baschek R, Hinke A, Pottek T, Kliesch S, Dieckmann KP,

Albers P, Knutzen B, Weinknecht S, Schmoll HJ, Beyer J, Ruebben H: (2006) Single

agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German

Testicular Cancer Study Group (GTCSG). ANN ONCOL, 17: 276-280 IF: 5,179, anteiliger IF: 0,15697

6. Mueller LP, Luetzkendorf J, Mueller T, Reichelt K, Simon H, Schmoll HJ: (2006)

Presence of mesenchymal stem cells in human bone marrow after exposure to

chemotherapy: evidence of resistance to apoptosis induction. STEM CELLS, 24: 2753-

65 16931776 IF: 7,924, anteiliger IF: 2,64107

7. Mueller T, Mueller LP, Luetzkendorf J, Voigt W, Simon H, Schmoll HJ: (2006) Loss of

Oct-3/4 expression in embryonal carcinoma cells is associated with induction of

cisplatin resistance. TUMOR BIOL, 27: 71-83 16557044 IF: 2,407, anteiliger IF: 0,80225

8. Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, von Pawel J, Giezek H,

Ahmed T, Chan CY: (2006) Comparison of an aprepitant regimen with a multiple-day

ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose

cisplatin treatment. ANN ONCOL, 17: 1000-1006 IF: 5,179, anteiliger IF: 1,72616

9. Schmoll HJ, Arnold D: (2006) Update on capecitabine in colorectal cancer.

ONCOLOGIST, 11: 1003-1009 IF: 5,206, anteiliger IF: 2,603

10. van Cutsem E, Dicato M, Arber N, Benson A, Cunningham D, Diaz-Rubio E, Glimelius

B, Goldberg R, Haller D, Haustermans K, Koo-Kang Y, Labianca R, Lang I, Minsky B,

Nordlinger B, Roth A, Rougier P, Schmoll HJ, Sobrero A, Tabernero J, Szawlowski A,

van de Velde C: (2006) The neo-adjuvant, surgical and adjuvant treatment of gastric

adenocarcinoma. Current expert opinion derived from the Seventh World Congress

on Gastrointestinal Cancer, Barcelona, 2005. ANN ONCOL, 17: vi 13-18 IF: 5,179, anteiliger IF: 0,08633

11. Voigt W, Kegel T, Maher G, Jordan K, Mueller L, Schmoll HJ: (2006) Bevacizumab plus

high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third-line salvage

chemotherapy induced an unexpected dramatic response in highly platinum

refractory germ-cell cancer. ANN ONCOL, 17: 531-533 IF: 5,179, anteiliger IF: 1,72616


Originalarbeiten

1. Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Schöffski P, Schmoll H, Van

Cutsem E, Köhne CH: (2007) Corrigendum to "Does a patient's self-reproted health-

related quality of life predict survival beyond key biomedical data in advanced

colorectal cancer?". EUR J CANCER, 43: 633 IF: 4,454, anteiliger IF: 0,21214

2. Jordan K, Grothe W, Schmoll HJ: (2007) Zytostatikaparavasate: Prophylaxe und

Therapie. ONKOLOGIE, 6: 55-58 IF: 1,227, anteiliger IF: 0,40896

3. Jordan K, Hinke A, Grothey A, Voigt W, Arnold D, Wolf HH, Schmoll HJ: (2007) A meta-

analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute

chemotherapy-induced emesis. SUPPORT CARE CANCER, 15: 1023-33 17205281 IF: 2,122, anteiliger IF: 0,70726

4. Jordan K, Schmoll HJ, Aapro MS: (2007) Comparative activity of antiemetic drugs.

CRIT REV ONCOL HEMAT, 61: 162-175 IF: 4,632, anteiliger IF: 1,54431

5. Jordan K, Sippel C, Schmoll HJ: (2007) Guidelines for antiemetic treatment of

chemotherapy-induced nausea and vomiting: past, present, and future

recommendations. ONCOLOGIST, 12: 1143-1150 IF: 4,876, anteiliger IF: 1,62517

6. Lorch JH, Thomas TO, Schmoll HJ: (2007) Bortezomib inhibits cell-cell adhesion and

cell migration and enhances epidermal growth factor receptor inhibitor-induced cell

death in squamous cell cancer. CANCER RES, 15: 727-734 IF: 7,672, anteiliger IF: 2,55708

7. Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A,

Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ: (2007) Phase III study of

capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus

oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study

Group. J CLIN ONCOL, 25: 4217-23 17548840 IF: 15,484, anteiliger IF: 5,16082

8. Punt CJ, Buyse M, Koehne CH, Hohenberger P, Labianca R, Schmoll HJ, Pahlman A,

Douillard JY: (2007) Endpoints in adjuvant treatment trials: a systematic review of the

literature in colon cancer and proposed definitions for future trials. JNCI-J NATL

CANCER I, 99: 998-1003 IF: 15,678, anteiliger IF: 0,87117

9. Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R,

Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M,

Sirzen F, Haller DG: (2007) Phase III trial of capecitabine plus oxaliplatin as adjuvant

therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J CLIN


10. Schmoll HJ, Sargent D: (2007) CAIRO and FOCUS - Author's reply. LANCET, 370: 1905 IF: 28,638, anteiliger IF: 14,319

11. Schmoll HJ, Sargent D: (2007) Single agent fluorouracil for first-line treatment of

advanced colorectal cancer as standard? LANCET, 370: 105-107 IF: 28,638, anteiliger IF: 14,319

12. Schmoll HJ, Schmiegel W: (2007) VII. Interdisziplinärer Expertenworkshop 2007

"Gastrointestinale Tumore" - Zusammenfassung. ONKOLOGIE, 30: 27 IF: 1,227, anteiliger IF: 0,6135

13. Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E,

Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PD, Kerr D,

Labianca R, Louvet C, Minsky B, Moore M, Nordlinger B, Pedrazzoli S, Roth A,

Rothenberg M, Rougier P, Schmoll HJ, Tabernero J, Tempero M, van de Velde C, Van

Laethem JL, Zalcberg J: (2007) The management of pancreatic cancer. Current expert

opinion and recommendations derived from the 8th World Congress on

Gastrointestinal Cancer, Barcelona 2006. ANN ONCOL, 18: vii1-vii10 IF: 4,875, anteiliger IF: 0,06251

14. Voigt W, Maher G, Wolf HH, Schmoll HJ: (2007) Human chorionic gonadotropin-

induced hyperthyroidism in germ cell cancer--a case presentation and review of the

literature. ONKOLOGIE, 30: 330-4 17585415 IF: 1,227, anteiliger IF: 0,40896


Originalarbeiten

1. Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, Martoni A,

Grothey A, Hinke A, Schmiegel W, Schmoll HJ, Porschen R: (2008) Efficacy of

oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with

metastatic colorectal cancer: A pooled analysis of randomized trials. J CLIN ONCOL,

20: 5910-5917 IF: 17,157, anteiliger IF: 0,57201

2. Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Martoni A, Grothey A,

Hinke A, Schmiegel W, Schmoll HJ: (2008) The combination of oxaliplatin with

capecitabine or 5-fluorouracil (5-FU)/ leucovorin in patients with metastastic

colorectal cancer (MCRC): a pooled analysis of randomized phase II-III trials. J CLIN


3. Arkenau HT, Graeven U, Kubicka S, Grothey A, Englisch-Fritz C, Kretzschmar A, Greil R,

Freier W, Seufferlein T, Hinke A, Schmoll HJ, Schmiegel W, Porschen R, Colorectal

Study Group AIO: (2008) Oxaliplatin in combination with 5-fluorouracil/leucovorin or

capecitabine in elderly patients with metastatic colorectal cancer. CLIN COLORECTAL

CANC, 7: 60-4 18279579 IF: 2,724, anteiliger IF: 0,07568

4. Arnold D, Höhler T, Dittrich C, Lordick F, Seufferlein T, Riemann J, Wöll E, Herrmann T,

Zubel A, Schmoll HJ: (2008) Cetuximab in combination with weekly 5-

fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced

colorectal cancer: a phase Ib/II study of the AIO GI Group. ANN ONCOL, 19: 1442-

9 18441330


5. Arnold D, Siewczynski R, Kubicka S, Hacker U, Schmoll HJ: (2008) Kolorektales

Karzinom - Primärtherapie bei fortgeschrittener Metastasierung. ONKOLOGIE, 31: 3-8 IF: 1,545, anteiliger IF: 0,51495

6. Cassidy J, Schmoll HJ, Van Cutsem E: (2008) Re: Should capecitabine replace

infusional flourouracil and leucovorin when combined with oxaliplatin in metastatic

colorectal cancer? J CLIN ONCOL, 26: 2228 IF: 17,157, anteiliger IF: 5,72014

7. Dietrich A, Mueller T, Paschke R, Kalinowski B, Behlendorf T, Reipsch F, Fruehauf A,

Schmoll HJ, Kloft C, Voigt W: (2008) 2-(4-(Tetrahydro-2H-pyran-2-yloxy)-undecyl)-

propane-1,3-diamminedichloroplatinum(II): a novel platinum compound that

overcomes cisplatin resistance and induces apoptosis by mechanisms different from

that of cisplatin. J MED CHEM, 51: 5413-22 18698754 IF: 4,898, anteiliger IF: 0,20412

8. Fizazi K, Oldenburg J, Dunant A, Chen I, Salvioni R, Hartmann JT, De Santis M,

Daugaard G, Flechon A, de Giorgi U, Tjulandin S, Schmoll HJ, Bouzy J, Fossa SD,

Fromont G: (2008) Assessing prognosis and optimizing treatment in patients with

postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of

the sCR2 international study. ANN ONCOL, 19: 259-264 IF: 4,935, anteiliger IF: 0,12656

9. Haller DG, Cassidy J, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM, Rothenberg

ML, Saltz LB, Schmoll HJ, Allegra C, Bertino JR, Douillard JY, Gustavsson BG, Milano G,

O'Connell M, Rustum Y, Tabernero J, Gilberg F, Sirzen F, Twelves C: (2008) Potential

regional differences for the tolerability profiles of fluoropyrimidines. J CLIN ONCOL,

26: 2118-2123 IF: 17,157, anteiliger IF: 0,31779

10. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I,

Bokemeyer C, Cavallin-Stahl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S,

Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann

KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fossa SD, Gardia Del Muro X,

Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M,

Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG,

Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M,

Laguna P, Leiva Galvis O, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai

N, Oliver T, Ondrus D, Oosterhof GO, Paz Ares L, Pizzocaro G, Pont J, Pottek T, Powles

T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll

HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P,

Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H: (2008)

European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A

Report of the Second Meeting of the European Germ Cell Cancer Consensus Group

(EGCCCG): Part II. EUR UROL, 53: 497-513 IF: 6,512, anteiliger IF: 0,0268

11. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I,

Bokemeyer C, Cavallin-Stahl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S,

Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann

KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fossa SD, Gardia Del Muro X,

Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M,

Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG,

Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M,

Laguna P, Leiva Galvis O, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai

N, Oliver T, Ondrus D, Oosterhof GO, Paz Ares L, Pizzocaro G, Pont J, Pottek T, Powles

T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll

HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P,

Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H: (2008)

European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A

Report of the Second Meeting of the European Germ Cell Cancer Consensus Group

(EGCCCG): Part I. EUR UROL, 53: 478-496 IF: 6,512, anteiliger IF: 0,0268

12. Müller CI, Schulmann K, Reinacher-Schick A, Andre N, Arnold D, Tannapfel A, Arkenau

H, Hahn SA, Schmoll HJ, Porschen R, Schmiegel W, Graeven U: (2008) Predictive and

prognostic value of microsatellite instability in patients with advanced colorectal

cancer treated with a fluoropyrimidine and oxaliplatin containing first-line

chemotherapy . A report of the AIO Colorectal Study Group. INT J COLORECTAL DIS,

23: 1033-39 IF: 1,767, anteiliger IF: 0,05891

13. Schmiegel W, Reinacher-Schick A, Arnold D, Graeven U, Heinemann V, Porschen R,

Riemann J, Rödel C, Sauer R, Wieder M, Schmitt W, Schmoll HJ, Seufferlein T, Kopp I,

Pox C: (2008) [Update S3-guideline "colorectal cancer" 2008]. Z GASTROENTEROL, 46:

799-840 18759205 IF: 0,88, anteiliger IF: 0,02257

14. Valentini V, Beets-Tan R, Borras JM, Krivokapic Z, Leer JW, Pahlman L, Rödel C,

Schmoll HJ, Scott N, Velde CV, Verfaillie C: (2008) Evidence and research in rectal

cancer. RADIOTHER ONCOL, 87: 449-474 IF: 3,99, anteiliger IF: 0,14781

15. Van Cutsem E, Dicato M, Haustermans K, Arber N, Bosset JF, Cunningham D, De

Gramont A, Diaz-Rubio E, Ducreux M, Goldberg R, Glynne-Jones R, Haller D, Kang YK,

Kerr D, Labianca R, Minsky BD, Moore M, Nordlinger B, Rougier P, Scheithauer W,

Schmoll HJ, Sobrero A, Tabernero J, Tempero M, Van de Velde C, Zalcberg J: (2008)

The diagnosis and management of rectal cancer: expert discussion and

recommendations derived from the 9th World Congress on Gastrointestinal Cancer,

Barcelona, 2007. ANN ONCOL, 19: vi1-vi8 IF: 4,935, anteiliger IF: 0,06856

16. Voigt W, Jordan K, Schmoll HJ: (2008) Advances in the prognosis and treatment of

medullary or anaplastic thyroid cancer. EUR J ENDOCRINOL, 4: 66-69 IF: 3,791, anteiliger IF: 1,26354


Originalarbeiten

1. Arnold D, Voigt W, Kiewe P, Behrmann C, Lindemann S, Reif S, Wiesinger H, Giurescu

M, Thiel E, Schmoll HJ: (2009) Weekly administration of sagopilone (ZK-EPO), a fully

synthetic epothilone, in patients with refractory solid tumours: results of a phase I

trial. BRIT J CANCER, 101: 1241-7 19773753 IF: 4,346, anteiliger IF: 1,44852

2. Dansranjavin T, Krehl S, Müller T, Müller LP, Schmoll HJ, Dammann RH: (2009) The

role of promoter CpG methylation in the epigenetic control of stem cell related genes

during differentiation. CELL CYCLE, 15: 916-924 IF: 4,087, anteiliger IF: 0,34065

3. Jahn P, Renz P, Stukenkemper J, Book K, Kuss O, Jordan K, Horn I, Thoke-Colberg A,

Schmoll HJ, Landenberger M: (2009) Reduction of chemotherapy-induced anorexia,

nausea, and emesis through a structured nursing intervention: a cluster-randomized

multicenter trial. SUPPORT CARE CANCER, 17: 1543-52 19629539 IF: 2,089, anteiliger IF: 0,08706

4. Jordan K, Kinitz I, Voigt W, Behlendorf T, Wolf HH, Schmoll HJ: (2009) Safety and

efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in

highly and moderately emetogenic multiple-day chemotherapy. EUR J CANCER, 45:

1184-7 19135359 IF: 4,121, anteiliger IF: 1,37353

5. Jordan K, Behlendorf T, Müller F, Schmoll HJ: (2009) Anthracycline extravasation

injuries: management with dexrazoxane. THER CLIN RISK MANAG, 5: 361-6 19536310 IF: 0, anteiliger IF: 0

6. Keysser G, Müller L, Schendel M, Schmoll HJ: (2009) [Therapeutic application of

mesenchymal stromal cells in autoimmune disease: rationale and initial clinical

experience]. Z RHEUMATOL, 68: 220, 222-7 19384552 IF: 0,401, anteiliger IF: 0,13365

7. Mueller T, Luetzkendorf J, Nerger K, Schmoll HJ, Mueller LP: (2009) Analysis of OCT4

expression in an extended panel of human tumor cell lines from multiple entities and

in human mesenchymal stem cells. CELL MOL LIFE SCI, 66: 495-503 19023518 IF: 6,09, anteiliger IF: 0,6768

8. Robertson JD, Botwood NA, Rothenberg ML, Schmoll HJ: (2009) Phase III trial of

FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients

with metastatic colorectal cancer: HORIZON III. CLIN COLORECTAL CANC, 8: 59-60 IF: 1,764, anteiliger IF: 0,58794

9. Schmoll HJ, Arnold D: (2009) When Wishful Thinking Leads to a Misty-Eyed Appraisal:

The Story of the Adjuvant Colon Cancer Trials With Edrecolomab. J CLIN ONCOL, 27:

1-4


10. Schmoll HJ, Jordan K: (2009) Current treatment of high risk testis cancer. EUR J

CANCER, 45 Suppl 1: 433-5 19775661 IF: 4,121, anteiliger IF: 2,0605

11. Schmoll HJ, Jordan K, Huddart R, Laguna MP, Horwich A, Fizazi K, Kataja V, ESMO

Guidelines Working Group: (2009) Testicular seminoma: ESMO clinical

recommendations for diagnosis, treatment and follow-up. ANN ONCOL, 20 Suppl 4:

83-8 19454474 IF: 5,647, anteiliger IF: 1,88215

12. Schmoll HJ, Jordan K, Huddart R, Laguna MP, Horwich A, Fizazi K, Kataja V, ESMO

Guidelines Working Group: (2009) Testicular non-seminoma: ESMO clinical

recommendations for diagnosis, treatment and follow-up. ANN ONCOL, 20 Suppl 4:

89-96 19454475 IF: 5,647, anteiliger IF: 1,88215

13. Schmoll HJ, Schmiegel W: (2009) Gastrointestinal tumors. Foreward. ONKOLOGIE, 32:

1 IF: 1,234, anteiliger IF: 0,617

14. Seliger G, Mueller LP, Kegel T, Kantelhardt EJ, Grothey A, Groe R, Strauss HG, Koelbl

H, Thomssen C, Schmoll HJ: (2009) Phase 2 trial of docetaxel, gemcitabine, and

oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated

epithelial ovarian cancer. INT J GYNECOL CANCER, 19: 1446-53 20009905 IF: 2,179, anteiliger IF: 0,72626

15. Trarbach T, Schmoll HJ: (2009) Rectal cancer and synchronous metastases: resection

of primary tumor or not? GASTROEN CLIN BIOL, 33: 1098-1100 IF: 0,928, anteiliger IF: 0,464

16. Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM, Haustermans K,

Maingon P, Overgaard J, Pahlman L, Quirke P, Schmoll HJ, Sebag-Montefiore D,

Taylor I, van Cutsem E, van de Velde C, Cellini N, Latini P, Scientific C: (2009)

Multidisciplinary rectal cancer management: 2nd European Rectal Cancer Consensus

Conference (EURECA-CC2). RADIOTHER ONCOL, 92: 148-163 IF: 4,343, anteiliger IF: 0,08517

17. Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, De Gramont

A, Diaz-Rubio E, Ducreux M, Gruenberger T, Haller D, Haustermans K, Hoff P, Kerr D,

Labianca R, Moore M, Nordlinger B, Ohtsu A, Rougier P, Scheithauer W, Schmoll HJ,

Sobrero A, Tabernero J, van de Velde C: (2009) The management of hepatocellular

carcinoma. Current expert opinion and recommendations derived from the 10th

World Congress on Gastrointestinal Cancer, Barcelona 2008. ANN ONCOL, 20: vii1-

vii6 IF: 5,647, anteiliger IF: 0,08558


Originalarbeiten

1. Arnold D, Schmoll HJ, Lang H, Knoefel WT, Ridwelski K, Trarbach T, Staib L, Kirchner T,

Geissler M, Seufferlein T, Amthauer H, Riess H, Schlitt HJ, Piso P: (2010) Spezielle

Therapiesituationen beim metastasierten kolorektalen Karzinom. ONKOLOGIE, 33: 8-

18 IF: 1,156, anteiliger IF: 0,03212

2. Bukur J, Loeffler D, Massa C, Mueller L, Riemann D, Schmoll HJ, Seliger B: (2010)

"Tumor immunology meets oncology IV", 23rd and 24th May 2008 Martin Luther

University Halle-Wittenberg, Halle, Germany. CANCER IMMUNOL IMMUN, 59: 955-

62 18751976 IF: 4,293, anteiliger IF: 0,28626

3. Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, Marreaud S,

Collette L, Lluch JR, Bokemeyer C, Schmoll HJ: (2010) A randomized phase III study

comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and

ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell

cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974).

ANN ONCOL, 22: 1054-1061 IF: 6,452, anteiliger IF: 2,15045

4. Jordan K, Grothey A, Pelz T, Lautenschläger C, Franke U, Schöber C, Schmoll HJ:

(2010) Impact of quality of life parameters and coping strategies on

postchemotherapy nausea and vomiting. EUR J CANCER CARE, 19: 603-9 19725867 IF: 1,138, anteiliger IF: 0,3793

5. Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J, Kegel T, Schmoll HJ: (2010)

The NK-1 receptor-antagonist aprepitant in high-dose (HD) chemotherapy (HD

melphalan and HD T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and

safety of a triple antiemetic combination. BONE MARROW TRANSPL, 13: 1-6 IF: 3,66, anteiliger IF: 1,21988

6. Jordan K, Wolf HH, Voigt W, Kegel T, Mueller LP, Behlendorf T, Sippel C, Arnold D,

Schmoll HJ: (2010) Bevacizumab in combination with sequential high-dose

chemotherapy in solid cancer, a feasibility study. BONE MARROW TRANSPL, 45:

1704-9 20228848 IF: 3,66, anteiliger IF: 1,21988

7. Lützkendorf J, Müller LP, Müller T, Caysa H, Nerger K, Schmoll HJ: (2010) Growth

inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal

stem cells requires their substantial intratumoral presence. J CELL MOL MED, 14:

2292-304 19508388 IF: 4,608, anteiliger IF: 1,53585

8. Matuszczyk A, Petersen S, Voigt W, Kegel T, Dralle H, Schmoll HJ, Bockisch A, Mann K:

(2010) Chemotherapy with paclitaxel and gemcitabine in progressive medullary and

thyroid carcinoma of the follicular epithelium. HORM METAB RES, 42: 61-4 19735058


9. Mueller T, Mueller LP, Holzhausen HJ, Witthuhn R, Albers P, Schmoll HJ: (2010)

Histological evidence for the existence of germ cell tumor cells showing embryonal

carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity.

HISTOCHEM CELL BIOL, 134: 197-204 20532795 IF: 4,727, anteiliger IF: 1,57551

10. Peinert S, Grothe W, Stein A, Müller LP, Ruessel J, Voigt W, Schmoll HJ, Arnold D:

(2010) Safety and efficacy of weekly 5-fluorouracil/folinic acid/oxaliplatin/irinotecan

in the first-line treatment of gastrointestinal cancer. THER ADV MED ONCOL, 2: 161-

74 21789132 IF: 0, anteiliger IF: 0

11. Reinacher-Schick A, Arnold D, Trarbach T, Ridwelski K, Bruch HP, Kirchner T, Kubicka

S, Schmoll HJ: (2010) Adjuvante Therapie des Kolonkarzinoms. ONKOLOGIE, 33: 2-7 IF: 1,156, anteiliger IF: 0,38529

12. Schmiegel W, Pox C, Reinacher-Schick A, Adler G, Arnold D, Fleig W, Fölsch UR,

Frühmorgen P, Graeven U, Heinemann V, Hohenberger W, Holstege A, Junginger T,

Kopp I, Kühlbacher T, Porschen R, Propping P, Riemann JF, Rödel C, Sauer R,

Sauerbruch T, Schmitt W, Schmoll HJ, Seufferlein T, Zeitz M, Selbmann HK: (2010) S3

guidelines for colorectal carcinoma: results of an evidence-based consensus

conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z

GASTROENTEROL, 48: 65-136 20072998 IF: 1,131, anteiliger IF: 0,01571

13. Schmoll HJ, Jordan K, Huddart R, Pes MPL, Horwich A, Fizazi K, Kataja V, ESMO

Guidelines Working Group: (2010) Testicular non-seminoma: ESMO Clinical Practice

Guidelines for diagnosis, treatment and follow-up. ANN ONCOL, 21 Suppl 5: v147-

54 20555066 IF: 6,452, anteiliger IF: 2,15045

14. Schmoll HJ, Jordan K, Huddart R, Pes MPL, Horwich A, Fizazi K, Kataja V, ESMO

Guidelines Working Group: (2010) Testicular seminoma: ESMO Clinical Practice

Guidelines for diagnosis, treatment and follow-up. ANN ONCOL, 21 Suppl 5: v140-

6 20555065 IF: 6,452, anteiliger IF: 2,15045

15. Van Cutsem E, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F, De Gramont A,

Diaz-Rubio E, Ducreux M, Geva R, Glimelius B, Jones RG, Grothey A, Gruenberger T,

Haller D, Haustermans K, Labianca R, Lenz HJ, Minsky B, Nordlinger B, Ohtsu A,

Pavlidis N, Rougier P, Schmiegel W, van de Velde C, Schmoll HJ, Sobrero A, Tabernero

J: (2010) Molecular markers and biological targeted therapies in metastatic colorectal

cancer: expert opinion and recommendations derived from the 11th ESMO/World

Congress on Gastrointestinal Cancer, Barcelona 2009. ANN ONCOL, 21: v1-10 IF: 6,452, anteiliger IF: 0,08273

16. Voigt W, Lorenz K, Schmoll HJ: (2010) Therapie des Schilddrüsenkarzinoms.

TUMORDIAGN THER, 1: 18-22


17. Zwierzina H, Bardelli A, Ciardiello F, Gariboldi M, Hakansson L, Lambrechts D, Lind GE,

Loeffler-Ragg J, Schmoll HJ, Siena S, Tabernero J, van Cutsem E: (2010) Molecularly

targeted therapies for colorectal cancer: Strategies for implementing translational

research in clinical trials. CURR OPIN MOL THER, 12: 703-11 21154162 IF: 4,023, anteiliger IF: 0,13413


Originalarbeiten

1. Abouassaly R, Fossa SD, Giwercman A, Kollmannsberger C, Motzer RJ, Schmoll HJ,

Sternberg CN: (2011) Sequelae of treatment in long-term survivors of testis cancer.

EUR UROL, 60: 516-26 21684072 IF: 8,493, anteiliger IF: 0,56631

2. Arnold D, Fietkau R, Hegewisch-Becker S, Höhler T, Knoefel WT, Kubicka S, Lang H,

Liersch T, Luster M, Oettle H, Reinacher-Schick A, Ridwelski K, Riess H, Rödel C,

Rüschoff J, Schmiegel W, Schmoll HJ, Vanhoefer U: (2011) Gastrointestinale Tumore -

interdisziplinäre Diskussion neuer Daten. ONKOLOGIE, 34: 1-31 IF: 0,868, anteiliger IF: 0,01809

3. Arnold D, Fietkau R, Hegewisch-Becker S, Höhler T, Knoefel WT, Kubicka S, Lang H,

Liersch T, Luster M, Oettle H, Reinacher-Schick A, Ridwelski K, Riess H, Rödel C,

Rüschoff J, Schmiegel W, Schmoll HJ, Vanhoefer U: (2011) [Gastrointestinal tumors--

interdisciplinary discussion over new data]. ONKOLOGIE, 34 Suppl 3: 1-31 21577036 IF: 0,868, anteiliger IF: 0,01809

4. Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, Marreaud S,

Collette L, Lluch JRG, Bokemeyer C, Schmoll HJ: (2011) A randomized phase III study

comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and

ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell

cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974).

ANN ONCOL, 22: 1054-61 21059637 IF: 6,425, anteiliger IF: 2,14145

5. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F,

Rittweger K, Schmoll HJ: (2011) Capecitabine plus oxaliplatin compared with

fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J CLIN

ONCOL, 29: 1465-71 21383294 IF: 18,372, anteiliger IF: 6,12339

6. Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J, Kegel T, Schmoll HJ: (2011)

The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose

melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide):

efficacy and safety of a triple antiemetic combination. BONE MARROW TRANSPL, 46:

784-9 20838387


7. Keyszer G, Christopeit M, Fick S, Schendel M, Taute BM, Behre G, Müller LP, Schmoll

HJ: (2011) Treatment of severe progressive systemic sclerosis with transplantation of

mesenchymal stromal cells from allogeneic related donors: report of five cases.

ARTHRITIS RHEUM-US, 63: 2540-2 21547891 IF: 7,866, anteiliger IF: 2,62174

8. Rüssel J, Stein A, Behrmann C, Hauptmann S, Krummenerl P, Schmoll HJ, Arnold D:

(2011) Inflammatory lesions of the peritoneum mimic carcinomatosis after treatment

with intravenous chemotherapy and intraperitoneal catumaxomab. J CLIN ONCOL,

29: e644-6 21606410 IF: 18,372, anteiliger IF: 1,22504

9. Schmoll HJ, Heissner K: (2011) Current treatment of stage I testicular seminoma.

ONKOLOGIE, 34: 495-6 21985846 IF: 0,868, anteiliger IF: 0,434

10. Schmoll HJ, Osanto S, Kawai K, Einhorn L, Fizazi K: (2011) Advanced seminoma and

nonseminoma: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai

2009. UROLOGY, 78: S456-68 21986225 IF: 2,428, anteiliger IF: 0,80925

11. Stein A, Hiemer S, Schmoll HJ: (2011) Adjuvant therapy for early colon cancer: current

status. DRUGS, 71: 2257-75 22085384 IF: 4,226, anteiliger IF: 1,40853

12. Surov A, Fiedler E, Holzhausen HJ, Ruschke K, Schmoll HJ, Spielmann RP: (2011)

Metastases to the breast from non-mammary malignancies: primary tumors,

prevalence, clinical signs, and radiological features. ACAD RADIOL, 18: 565-

74 21393030 IF: 1,692, anteiliger IF: 0,14103

13. Tempero MA, Berlin J, Ducreux M, Haller D, Harper P, Khayat D, Schmoll HJ, Sobrero

A, Van Cutsem E: (2011) Pancreatic cancer treatment and research: an international

expert panel discussion. ANN ONCOL, 22: 1500-6 21199884 IF: 6,425, anteiliger IF: 0,30601

14. Van Cutsem E, Dicato M, Geva R, Arber N, Bang Y, Benson A, Cervantes A, Diaz-Rubio

E, Ducreux M, Glynne-Jones R, Grothey A, Haller D, Haustermans K, Kerr D,

Nordlinger B, Marshall J, Minsky BD, Kang YK, Labianca R, Lordick F, Ohtsu A, Pavlidis

N, Roth A, Rougier P, Schmoll HJ, Sobrero A, Tabernero J, Van de Velde C, Zalcberg J:

(2011) The diagnosis and management of gastric cancer: expert discussion and

recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer,

Barcelona, 2010. ANN ONCOL, 22 Suppl 5: v1-9 21633049 IF: 6,425, anteiliger IF: 0,07934


Originalarbeiten

1. Calabrò F, Albers P, Bokemeyer C, Martin C, Einhorn LH, Horwich A, Krege S, Schmoll

HJ, Sternberg CN, Daugaard G: (2012) The contemporary role of chemotherapy for

advanced testis cancer: a systematic review of the literature. EUR UROL, 61: 1212-

21 22464311 IF: 10,476, anteiliger IF: 0,43659

2. de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ,

Cunningham D, Cartwright TH, Hecht JR, Rivera F, Im SA, Bodoky G, Salazar R,

Maindrault-Goebel F, Shacham-Shmueli E, Bajetta E, Makrutzki M, Shang A, André T,

Hoff PM: (2012) Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant

treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. LANCET


3. Nagtegaal ID, Quirke P, Schmoll HJ: (2012) Has the new TNM classification for

colorectal cancer improved care? NAT REV CLIN ONCOL, 9: 119-23 22009076 IF: 15,031, anteiliger IF: 5,00983

4. Saini KS, Taylor C, Ramirez AJ, Palmieri C, Gunnarsson U, Schmoll HJ, Dolci SM,

Ghenne C, Metzger-Filho O, Skrzypski M, Paesmans M, Ameye L, Piccart-Gebhart MJ,

de Azambuja E: (2012) Role of the multidisciplinary team in breast cancer

management: results from a large international survey involving 39 countries. ANN


5. Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I,

Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson

J, Van Cutsem E: (2012) Cediranib with mFOLFOX6 versus bevacizumab with

mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a

double-blind, randomized phase III study (HORIZON III). J CLIN ONCOL, 30: 3588-

95 22965961 IF: 18,038, anteiliger IF: 6,01207

6. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K,

Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG,

Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W,

Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H,

Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D,

Pfeiffer P, Souglakos I, Turhal S, Cervantes A: (2012) ESMO Consensus Guidelines for

management of patients with colon and rectal cancer. a personalized approach to

clinical decision making. ANN ONCOL, 23: 2479-516 23012255 IF: 7,384, anteiliger IF: 2,46109

7. Stein A, Glockzin G, Wienke A, Arnold D, Edelmann T, Hildebrandt B, Hollerbach S,

Illerhaus G, Königsrainer A, Richter M, Schlitt HJ, Schmoll HJ: (2012) Treatment with

bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer:

presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.

BMC CANCER, 12: 356 22897915 IF: 3,333, anteiliger IF: 1,11089

8. Stein A, Hiemer S, Jordan K, Arnold D, Schmoll HJ: (2012) Administration of

chemotherapy by an arteriovenous fistula in a patient with metastatic rectal cancer

after life-threatening, port thrombosis-associated cava superior syndrome. An option

for patients without possibility of peripheral or central venous access. ONKOLOGIE,

35: 440-2 22846976 IF: 1, anteiliger IF: 0,3333


Originalarbeiten

1. Aapro MS, Schmoll HJ, Jahn F, Carides AD, Webb RT: (2013) Review of the efficacy of

aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a

range of tumor types. CANCER TREAT REV, 39: 113-7 23062719 IF: 6,466, anteiliger IF: 0,71859

2. Bernig T, Jahn F, Witkowsky S, Huehn R, Hentschel A, Kegel T, Schmoll HJ, Körholz D:

(2013) Treatment of adolescents and young adults (AYA) with cancer in a

multidisciplinary setting: on the way to a highly specialized AYA unit. KLIN PADIATR,

225: 335-8 24166088 IF: 0, anteiliger IF: 0

3. Christopeit M, Janssen N, Weber T, Bacher U, Lautenschläger C, Oehme A, Kekulé AS,

Schmoll HJ: (2013) Cyclosporine area under the curve after allogeneic hematopoietic

stem cell transplantation is an indicator of Epstein-Barr virus DNAemia. LEUKEMIA

LYMPHOMA, 54: 133-7 22721496 IF: 2,605, anteiliger IF: 0,86825

4. Christopeit M, Lindner A, Surov A, Weber T, Vehreschild MJGT, Bialek R, Schmoll HJ:

(2013) Right flank pain and high fever in a neutropenic patient with acute

lymphoblastic leukaemia. MYCOSES, 56: 90-2 22889321 IF: 1,805, anteiliger IF: 0,60161

5. Dralle H, Musholt TJ, Schabram J, Steinmüller T, Frilling A, Simon D, Goretzki PE,

Niederle B, Scheuba C, Clerici T, Hermann M, Kußmann J, Lorenz K, Nies C, Schabram

P, Trupka A, Zielke A, Karges W, Luster M, Schmid KW, Vordermark D, Schmoll HJ,

Mühlenberg R, Schober O, Rimmele H, Machens A, German Societies of General and

Visceral Surgery Endocrinology Nuclear Medicine Pathology Radiooncology

Oncological Hematology and the German Thyroid Cancer Patient Support

Organization Ohne Schilddrüse leben e.V: (2013) German Association of Endocrine

Surgeons practice guideline for the surgical management of malignant thyroid

tumors. LANGENBECK ARCH SURG, 398: 347-75 23456424 IF: 2,16, anteiliger IF: 0,02881

6. Jürgensmeier JM, Schmoll HJ, Robertson JD, Brooks L, Taboada M, Morgan SR, Wilson

D, Hoff PM: (2013) Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in

mCRC studies comparing cediranib, bevacizumab and chemotherapy. BRIT J CANCER,

108: 1316-23 23449351 IF: 4,817, anteiliger IF: 0,26766

7. Oldenburg J, Fosså SD, Nuver J, Heidenreich A, Schmoll HJ, Bokemeyer C, Horwich A,

Beyer J, Kataja V, ESMO Guidelines Working Group: (2013) Testicular seminoma and

non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and

follow-up. ANN ONCOL, 24 Suppl 6: vi125-32 24078656 IF: 6,578, anteiliger IF: 0,2743

8. Pox C, Aretz S, Bischoff SC, Graeven U, Hass M, Heußner P, Hohenberger W, Holstege

A, Hübner J, Kolligs F, Kreis M, Lux P, Ockenga J, Porschen R, Post S, Rahner N,

Reinacher-Schick A, Riemann JF, Sauer R, Sieg A, Scheppach W, Schmitt W, Schmoll

HJ, Schulmann K, Tannapfel A, Schmiegel W, Leitlinienprogramm Onkologie der

AWMF, Deutschen Krebsgesellschaft e. V, Deutschen Krebshilfe e. V: (2013) [S3-

guideline colorectal cancer version 1.0]. Z GASTROENTEROL, 51: 753-854 23955142 IF: 1,671, anteiliger IF: 0,02055

9. Schmiegel W, Reinacher-Schick A, Arnold D, Kubicka S, Freier W, Dietrich G, Geißler

M, Hegewisch-Becker S, Tannapfel A, Pohl M, Hinke A, Schmoll HJ, Graeven U: (2013)

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with

bevacizumab is effective and safe as first-line therapy for metastatic colorectal

cancer: a randomized phase II study of the AIO colorectal study group. ANN ONCOL,

24: 1580-7 23463625 IF: 6,578, anteiliger IF: 0,19937

10. Stein A, Schmoll HJ: (2013) Systemic treatment of liver metastases from colorectal

cancer. THER ADV MED ONCOL, 5: 193-203 23634197 IF: 0, anteiliger IF: 0

11. Van Cutsem E, Borràs JM, Castells A, Ciardiello F, Ducreux M, Haq A, Schmoll HJ,

Tabernero J: (2013) Improving outcomes in colorectal cancer: where do we go from

here? EUR J CANCER, 49: 2476-85 23642327 IF: 4,819, anteiliger IF: 0,26778

12. van de Velde CJH, Aristei C, Boelens PG, Beets-Tan RGH, Blomqvist L, Borras JM, van

den Broek CBM, Brown G, Coebergh JW, Cutsem EV, Espin E, Gore-Booth J, Glimelius

B, Haustermans K, Henning G, Iversen LH, Han van Krieken J, Marijnen CAM,

Mroczkowski P, Nagtegaal I, Naredi P, Ortiz H, Påhlman L, Quirke P, Rödel C, Roth A,

Rutten HJT, Schmoll HJ, Smith J, Tanis PJ, Taylor C, Wibe A, Gambacorta MA,

Meldolesi E, Wiggers T, Cervantes A, Valentini V, European Registration of Cancer

Care: (2013) EURECCA colorectal: multidisciplinary mission statement on better care

for patients with colon and rectal cancer in Europe. EUR J CANCER, 49: 2784-

90 23769991 IF: 4,819, anteiliger IF: 0,0459


Originalarbeiten

1. Bach AG, Schmoll HJ, Beckel C, Behrmann C, Spielmann RP, Wienke A, Abbas J, Surov

A: (2014) Pulmonary embolism in oncologic patients: frequency and embolus burden

of symptomatic and unsuspected events. ACTA RADIOL, 55: 45-53 23864061 IF: 1,603, anteiliger IF: 0,08913

2. Breugom AJ, Boelens PG, van den Broek CBM, Cervantes A, Van Cutsem E, Schmoll

HJ, Valentini V, van de Velde CJH: (2014) Quality assurance in the treatment of

colorectal cancer: the EURECCA initiative. ANN ONCOL, 25: 1485-92 24671742 IF: 7,04, anteiliger IF: 0,39142

3. Chu E, Haller D, Cartwright T, Twelves C, Cassidy J, Sun W, Saif MW, McKenna E, Lee

S, Schmoll HJ: (2014) Epidemiology and natural history of central venous access

device use and infusion pump function in the NO16966 trial. BRIT J CANCER, 110:

1438-45 24548866 IF: 4,836, anteiliger IF: 1,61184

4. Kreissl MC, Jacob C, Führer D, Karges W, Luster M, Lux MP, Mann K, Mittendorf T,

Schott M, Spitzweg C, Schmoll HJ: (2014) Best supportive care from the

conservative/non-surgical perspective and its costs in the treatment of patients with

advanced medullary thyroid cancer: results of a Delphi panel. ONCOL RES TREAT, 37:

316-22 24903762 IF: 0, anteiliger IF: 0

5. Lestuzzi C, Vaccher E, Talamini R, Lleshi A, Meneguzzo N, Viel E, Scalone S, Tartuferi L,

Buonadonna A, Ejiofor L, Schmoll HJ: (2014) Effort myocardial ischemia during

chemotherapy with 5-fluorouracil: an underestimated risk. ANN ONCOL, 25: 1059-

64 24558023 IF: 7,04, anteiliger IF: 2,34643

6. Riemann JF, Schröder C, Kallenbach M, Giersiepen K, Schmoll HJ: (2014) Benefits and

risks of colorectal cancer screening. ONCOL RES TREAT, 37 Suppl 3: 11-20 25195828 IF: 0, anteiliger IF: 0

7. Schmoll HJ, Stein A: (2014) Colorectal cancer in 2013: Towards improved drugs,

combinations and patient selection. NAT REV CLIN ONCOL, 11: 79-80 24445520 IF: 14,18, anteiliger IF: 7,09

8. Schmoll HJ, Twelves C, Sun W, O'Connell MJ, Cartwright T, McKenna E, Saif M, Lee S,

Yothers G, Haller D: (2014) Effect of adjuvant capecitabine or fluorouracil, with or

without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of

oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from

four randomised controlled trials. LANCET ONCOL, 15: 1481-92 25456367 IF: 24,69, anteiliger IF: 8,22918

9. Schmoll HJ, Wittig B, Arnold D, Riera-Knorrenschild J, Nitsche D, Kroening H, Mayer F,

Andel J, Ziebermayr R, Scheithauer W: (2014) Maintenance treatment with the

immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with

metastatic colorectal carcinoma and disease control after chemotherapy: a

randomised, double-blind, placebo-controlled trial. J CANCER RES CLIN, 140: 1615-

24 24816725 IF: 3,081, anteiliger IF: 1,0269

10. Stein A, Arnold D, Thuss-Patience PC, Moehler M, Grothe W, Seufferlein T, Reinacher-

Schick A, Geissler M, Hofheinz RD, Schmoll HJ: (2014) Docetaxel, oxaliplatin and

capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal

cancer: results of a multicenter phase I/II study. ACTA ONCOL, 53: 392-8 24024696 IF: 2,997, anteiliger IF: 0,9989

11. van de Velde CJH, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blomqvist L,

Beets-Tan RGH, van den Broek CBM, Brown G, Van Cutsem E, Espin E, Haustermans

K, Glimelius B, Iversen LH, van Krieken JH, Marijnen CAM, Henning G, Gore-Booth J,

Meldolesi E, Mroczkowski P, Nagtegaal I, Naredi P, Ortiz H, Påhlman L, Quirke P,

Rödel C, Roth A, Rutten H, Schmoll HJ, Smith JJ, Tanis PJ, Taylor C, Wibe A, Wiggers T,

Gambacorta MA, Aristei C, Valentini V: (2014) EURECCA colorectal: multidisciplinary

management: European consensus conference colon & rectum. EUR J CANCER, 50:

1.e1-1.e34 24183379 IF: 5,417, anteiliger IF: 0,05417


Originalarbeiten

1. Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D: (2015) Aprepitant and

fosaprepitant: a 10-year review of efficacy and safety. ONCOLOGIST, 20: 450-

8 25795636 IF: 4,789, anteiliger IF: 0,39892

2. Bauer A, Vordermark D, Seufferlein T, Schmoll HJ, Dralle H, Mau W, Unverzagt S,

Boese S, Fach EM, Landenberger M: (2015) Trans-sectoral care in patients with

colorectal cancer: Protocol of the randomized controlled multi-center trial Supportive

Cancer Care Networkers (SCAN). BMC CANCER, 15: 997 26694748 IF: 3,265, anteiliger IF: 0,13615

3. Grünwald V, Keilholz U, Boehm A, Guntinas-Lichius O, Hennemann B, Schmoll HJ,

Ivanyi P, Abbas M, Lehmann U, Koch A, Karch A, Zörner A, Gauler TC: (2015)

TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and

cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the

head and neck (SCCHN) of the German SCCHN Group (AIO). ANN ONCOL, 26: 561-

7 25527417 IF: 9,269, anteiliger IF: 0,28085

4. Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll HJ, Tveit KM,

Gibson F: (2015) A review of the evolution of systemic chemotherapy in the

management of colorectal cancer. CLIN COLORECTAL CANC, 14: 1-10 25579803


5. Haller DG, O'Connell MJ, Cartwright TH, Twelves CJ, McKenna EF, Sun W, Saif MW,

Lee S, Yothers G, Schmoll HJ: (2015) Impact of age and medical comorbidity on

adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of

individual patient data from four randomized, controlled trials. ANN ONCOL, 26: 715-

24 25595934 IF: 9,269, anteiliger IF: 3,08936

6. Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens

CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick

A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D: (2015) Maintenance

strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for

patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority,

open-label, phase 3 trial. LANCET ONCOL, 16: 1355-69 26361971 IF: 26,509, anteiliger IF: 0,5885

7. Jahn F, Jordan K, Behlendorf T, Globig C, Schmoll HJ, Müller-Tidow C, Jordan B: (2015)

Safety and Efficacy of Liposomal Cytarabine in the Treatment of Neoplastic

Meningitis. ONCOLOGY-BASEL, 89: 137-42 25791073 IF: 2,152, anteiliger IF: 0,14354

8. Renfro LA, Grothey A, Kerr D, Haller DG, André T, Van Cutsem E, Saltz L, Labianca R,

Loprinzi CL, Alberts SR, Schmoll H, Twelves C, Yothers G, Sargent DJ, Adjuvant Colon

Cancer Endpoints (ACCENT) Group, Adjuvant Colon Cancer Endpoints ACCENT Group:

(2015) Survival following early-stage colon cancer: an ACCENT-based comparison of

paênts versus a matched internaônal general populaôn†. ANN ONCOL, 26: 950-

8 25697217 IF: 9,269, anteiliger IF: 0,2206

9. Ruff P, Ferry DR, Lakomỳ R, Prausová J, Van Hazel GA, Hoff PM, Cunningham D,

Arnold D, Schmoll HJ, Moiseyenko VM, McKendrick JJ, Ten Tije AJ, Vishwanath RL,

Bhargava P, Chevalier S, Macarulla T, Van Cutsem E: (2015) Time course of safety and

efficacy of aflibercept in combination with FOLFIRI in patients with metastatic

colorectal cancer who progressed on previous oxaliplatin-based therapy. EUR J

CANCER, 51: 18-26 25466509 IF: 6,163, anteiliger IF: 0,13682

10. Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Hoersch

S, Rittweger K, Haller DG: (2015) Capecitabine Plus Oxaliplatin Compared With

Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results

of the NO16968 Randomized Controlled Phase III Trial. J CLIN ONCOL, 33: 3733-

40 26324362 IF: 20,982, anteiliger IF: 6,9933

11. Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY,

Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frödin JE, Ayers M, Nebozhyn M,

Peckitt C, Loboda A, Mauro DJ, Watkins DJ: (2015) A Randomized Phase II/III Study of

Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory,

KRAS Wild-Type, Metastatic Colorectal Cancer. JNCI-J NATL CANCER I, 107:

djv258 26405092 IF: 11,37, anteiliger IF: 0,21035

12. Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT,

Adams R, Saltz L, Goldberg RM, Punt CJA, Douillard JY, Hoff PM, Hecht JR, Hurwitz H,

Díaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos J, Falcone A, Tournigand C,

Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent DJ:

(2015) Individual patient data analysis of progression-free survival versus overall

survival as a first-line end point for metastatic colorectal cancer in modern

randomized trials: findings from the analysis and research in cancers of the digestive

system database. J CLIN ONCOL, 33: 22-8 25385741 IF: 20,982, anteiliger IF: 0,26857

13. Wittig B, Schmidt M, Scheithauer W, Schmoll HJ: (2015) MGN1703, an

immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside.

CRIT REV ONCOL HEMAT, 94: 31-44 25577571 IF: 5,039, anteiliger IF: 1,6795


Originalarbeiten

1. Ferreri AJM, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox

CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM,

Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G,

Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A,

Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G, International Extranodal

Lymphoma Study Group (IELSG): (2016) Chemoimmunotherapy with methotrexate,

cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS

lymphoma: results of the first randomisation of the International Extranodal

Lymphoma Study Group-32 (IELSG32) phase 2 trial. LANCET HAEMATOL, 3: e217-

27 27132696 IF: 7,123, anteiliger IF: 0,06624

2. Gormly KL, Coscia C, Wells T, Tebbutt N, Harvey JA, Wilson K, Schmoll HJ, Price T:

(2016) MRI rectal cancer in Australia and New Zealand: An audit from the PETACC-6

trial. J MED IMAG RADIAT ON, 60: 607-615 27397855 IF: 1,189, anteiliger IF: 0,06611

3. Lutz MP, Zalcberg JR, Glynne-Jones R, Ruers T, Ducreux M, Arnold D, Aust D, Brown

G, Bujko K, Cunningham C, Evrard S, Folprecht G, Gerard JP, Habr-Gama A,

Haustermans K, Holm T, Kuhlmann KF, Lordick F, Mentha G, Moehler M, Nagtegaal

ID, Pigazzi A, Pucciarelli S, Roth A, Rutten H, Schmoll HJ, Sorbye H, Van Cutsem E,

Weitz J, Otto F: (2016) Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer

Conference: Consensus recommendations on controversial issues in the primary

treatment of rectal cancer" [Eur J Cancer 63 (August 2016) 11-24]. EUR J CANCER, 68:

208-209 27717654

IF: 6,029, anteiliger IF: 0

4. Lutz MP, Zalcberg JR, Glynne-Jones R, Ruers T, Ducreux M, Arnold D, Aust D, Brown

G, Bujko K, Cunningham C, Evrard S, Folprecht G, Gerard JP, Habr-Gama A,

Haustermans K, Holm T, Kuhlmann KF, Lordick F, Mentha G, Moehler M, Nagtegaal

ID, Pigazzi A, Puciarelli S, Roth A, Rutten H, Schmoll HJ, Sorbye H, Van Cutsem E,

Weitz J, Otto F: (2016) Second St. Gallen European Organisation for Research and

Treatment of Cancer Gastrointestinal Cancer Conference: consensus

recommendations on controversial issues in the primary treatment of rectal cancer.

EUR J CANCER, 63: 11-24 27254838 IF: 6,029, anteiliger IF: 0,07175

5. Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R,

Stintzing S, Graeven U, Arnold D, von Weikersthal LF, Giessen-Jung C, Stahler A,

Schmoll HJ, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A: (2016) Outcome

according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants:

pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO

colorectal cancer study group. ANN ONCOL, 27: 1746-53 27358379 IF: 11,855, anteiliger IF: 0,26318

6. Moehler M, Gepfner-Tuma I, Maderer A, Thuss-Patience PC, Ruessel J, Hegewisch-

Becker S, Wilke H, Al-Batran SE, Rafiyan MR, Weißinger F, Schmoll HJ, Kullmann F,

von Weikersthal LF, Siveke JT, Weusmann J, Kanzler S, Schimanski CC, Otte M,

Schollenberger L, Koenig J, Galle PR: (2016) Sunitinib added to FOLFIRI versus FOLFIRI

in patients with chemorefractory advanced adenocarcinoma of the stomach or lower

esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker

program. BMC CANCER, 16: 699 27582078 IF: 3,288, anteiliger IF: 0,05754

7. Papamichael D, Renfro LA, Matthaiou C, Yothers G, Saltz L, Guthrie KA, Van Cutsem E,

Schmoll HJ, Labianca R, André T, O'Connell M, Alberts SR, Haller DG, Kountourakis P,

Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group: (2016) Validity of

Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients

from the ACCENT database. J GERIATR ONCOL, 7: 422-429 27468630 IF: 2,852, anteiliger IF: 0,06788

8. Quidde J, Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch

R, Steffens CC, Lange T, Dietrich G, Stoehlmacher J, Reinacher A, Tannapfel A,

Trarbach T, Marschner N, Schmoll HJ, Hinke A, Al-Batran SE, Arnold D: (2016) Quality

of life assessment in patients with metastatic colorectal cancer receiving

maintenance therapy after first-line induction treatment: a preplanned analysis of

the phase III AIO KRK 0207 trial. ANN ONCOL, 27: 2203-2210 27753609 IF: 11,855, anteiliger IF: 0,24658

9. Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll HJ, Douillard

JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone

A, Tebbutt NC, Punt CJA, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz

LB, de Gramont A, Sargent DJ, Lenz HJ: (2016) Body Mass Index Is Prognostic in

Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical

Trials in the ARCAD Database. J CLIN ONCOL, 34: 144-50 26503203 IF: 24,008, anteiliger IF: 0,36492

10. Shah MA, Renfro LA, Allegra CJ, André T, de Gramont A, Schmoll HJ, Haller DG,

Alberts SR, Yothers G, Sargent DJ: (2016) Impact of Patient Factors on Recurrence

Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer:

Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points

(ACCENT) Database. J CLIN ONCOL, 34: 843-53 26811529 IF: 24,008, anteiliger IF: 1,00113

11. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda

Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E,

Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K,

Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro

K, Normanno N, Österlund P, Oyen WJG, Papamichael D, Pentheroudakis G, Pfeiffer

P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J,

Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D: (2016) ESMO consensus

guidelines for the management of patients with metastatic colorectal cancer. ANN


12. Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R, Prausová J,

Moiseyenko VM, van Hazel G, Cunningham D, Arnold D, Schmoll HJ, Ten Tije AJ,

McKendrick J, Kröning H, Humblet Y, Grávalos C, Le-Guennec S, Andria M, Dochy E,

Vishwanath RL, Macarulla T, Tabernero J: (2016) Aflibercept Plus FOLFIRI vs. Placebo

Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of

Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who

had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based

Therapy. TARGET ONCOL, 11: 383-400 26706237 IF: 3,438, anteiliger IF: 0,05466

13. Widder M, Lützkendorf J, Caysa H, Unverzagt S, Wickenhauser C, Benndorf RA,

Schmoll HJ, Müller-Tidow C, Müller T, Müller LP: (2016) Multipotent mesenchymal

stromal cells promote tumor growth in distinct colorectal cancer cells by a β1-

integrin-dependent mechanism. INT J CANCER, 138: 964-75 26356035 IF: 6,513, anteiliger IF: 0,27159


Originalarbeiten

1. Bleiberg H, Decoster G, de Gramont A, Rougier P, Sobrero A, Benson A, Chibaudel B,

Douillard JY, Eng C, Fuchs C, Fujii M, Labianca R, Larsen AK, Mitchell E, Schmoll HJ,

Sprumont D, Zalcberg J: (2017) A need to simplify informed consent documents in

cancer clinical trials. A position paper of the ARCAD Group. ANN ONCOL, 28: 922-

930 28453700 IF: 11,855, anteiliger IF: 0,26318

2. Bonnetain F, Borg C, Adams RR, Ajani JA, Benson A, Bleiberg H, Chibaudel B, Diaz-

Rubio E, Douillard JY, Fuchs CS, Giantonio BJ, Goldberg R, Heinemann V, Koopman M,

Labianca R, Larsen AK, Maughan T, Mitchell E, Peeters M, Punt CJA, Schmoll HJ,

Tournigand C, de Gramont A: (2017) How health-related quality of life assessment

should be used in advanced colorectal cancer clinical trials. ANN ONCOL, 28: 2077-

2085 28430862 IF: 11,855, anteiliger IF: 0,18849

3. Emile JF, Julié C, Le Malicot K, Lepage C, Tabernero J, Mini E, Folprecht G, Van

Laethem JL, Dimet S, Boulagnon-Rombi C, Allard MA, Penault-Llorca F, Bennouna J,

Laurent-Puig P, Taieb J, PETACC8 Study Investigators, Austrian Breast and Colorectal

cancer Study Group (ABCSG), Belgian Group of Digestive Oncology (BGDO), Lone

Nørgård Petersen, Fédération Francophone de Cancérologie Digestive (FFCD),

Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER), Fédération

Nationale des Centres de Lutte Contre le Cancer Association Européenne de

Recherche en Oncologie (AERO), Arbeitsgemeinschaft Internistische Onkologie (AIO),

Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD),

Gruppo Oncologico dell'Italia Meridionale (GOIM), Istituto Oncologico Romagnolo

(IOR), Gruppo Cooperativo Chirurgico Italiano (GOCCI), Gruppo Oncologico Nord

Ovest (GONO), Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Gruppo

Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação

Oncológica (GCCD APIO), Grupo Español para el Tratamiento de los Tumores

Digestivos (TTD), John Allen Bridgewater: (2017) Prospective validation of a

lymphocyte infiltration prognostic test in stage III colon cancer patients treated with

adjuvant FOLFOX. EUR J CANCER, 82: 16-24 28651158 IF: 6,029, anteiliger IF: 0,06699

4. Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri

A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway

C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller

U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ,

Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M,

Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G, International

Extranodal Lymphoma Study Group (IELSG): (2017) Whole-brain radiotherapy or

autologous stem-cell transplantation as consolidation strategies after high-dose

methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma:

results of the second randomisation of the International Extranodal Lymphoma Study

Group-32 phase 2 trial. LANCET HAEMATOL, 4: e510-e523 29054815 IF: 7,123, anteiliger IF: 0,05522

5. Lützkendorf J, Wieduwild E, Nerger K, Lambrecht N, Schmoll HJ, Müller-Tidow C,

Müller LP: (2017) Resistance for Genotoxic Damage in Mesenchymal Stromal Cells Is

Increased by Hypoxia but Not Generally Dependent on p53-Regulated Cell Cycle

Arrest. PLoS One, 12: e0169921 28081228 IF: 2,806, anteiliger IF: 0,18716

6. Nagtegaal ID, Schmoll HJ: (2017) Colorectal cancer: What is the role of lymph node

metastases in the progression of colorectal cancer? NAT REV GASTRO HEPAT, 14:

633-634 28930293


7. Renfro LA, Goldberg RM, Grothey A, Sobrero A, Adams R, Seymour MT, Heinemann

V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R,

Tournigand C, Chibaudel B, Hoff PM, Kabbinavar FF, Falcone A, Tebbutt NC, Punt CJA,

Hecht JR, Souglakos J, Bokemeyer C, Van Cutsem E, Saltz L, de Gramont A, Sargent DJ,

ARCAD Clinical Trials Program: (2017) Clinical Calculator for Early Mortality in

Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the

Aide et Recherche en Cancérologie Digestive Database. J CLIN ONCOL, 35: 1929-

1937 28414610 IF: 24,008, anteiliger IF: 0,3073

8. Schaffrath J, Schmoll HJ, Voigt W, Müller LP, Müller-Tidow C, Mueller T: (2017)

Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin

sensitivity. PLoS One, 12: e0178930 28591197 IF: 2,806, anteiliger IF: 0,23374

9. Schmidt H, Boese S, Bauer A, Landenberger M, Lau A, Stoll O, Schmoll HJ, Mauz-

Koerholz C, Kuss O, Jahn P: (2017) Interdisciplinary care programme to improve self-

management for cancer patients undergoing stem cell transplantation: a prospective

non-randomised intervention study. EUR J CANCER CARE, 26: x 26857103 IF: 2,104, anteiliger IF: 0,08774

10. Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY,

Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frodin JE, Ayers M, Nebozhyn M,

Peckitt C, Loboda A, Watkins DJ: (2017) Dalotuzumab in chemorefractory KRAS exon

2 mutant colorectal cancer: Results from a randomised phase II/III trial. INT J

CANCER, 140: 431-439 27681944 IF: 6,513, anteiliger IF: 0,12765

11. Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R,

Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM,

Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A,

Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar

FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR, Fondation Aide et

Recherche en Cancerologie Digestive Group: (2017) Personalizing Survival Predictions

in Advanced Colorectal Cancer: The ARCAD Nomogram Project. JNCI-J NATL CANCER

I, x: x 29267900 IF: 12,589, anteiliger IF: 0,13114


Originalarbeiten

1. Schmoll HJ, Arnold D, de Gramont A, Ducreux M, Grothey A, O'Dwyer PJ, Van Cutsem

E, Hermann F, Bosanac I, Bendahmane B, Mancao C, Tabernero J: (2018) MODUL-a

multicenter randomized clinical trial of biomarker-driven maintenance therapy

following first-line standard induction treatment of metastatic colorectal cancer: an

adaptable signal-seeking approach. J CANCER RES CLIN, x: x 29644408 IF: 3,503, anteiliger IF: 1,16767


Comments and Letter

1. Schmoll HJ: (2010) S-1 for advanced colorectal cancer: do we need another oral

fluorouracil prodrug? LANCET ONCOL, 11: 808-809 IF: 17,764, anteiliger IF: 1,7764


Comments and Letter

1. Moehler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D, Aust D, Baier P,

Baretton G, Bernhardt J, Boeing H, Böhle E, Bokemeyer C, Bornschein J, Budach W,

Burmester E, Caca K, Diemer WA, Dietrich CF, Ebert M, Eickhoff A, Ell C, Fahlke J,

Feussner H, Fietkau R, Fischbach W, Fleig W, Flentje M, Gabbert HE, Galle PR, Geissler

M, Gockel I, Graeven U, Grenacher L, Gross S, Hartmann JT, Heike M, Heinemann V,

Herbst B, Herrmann T, Höcht S, Hofheinz RD, Höfler H, Höhler T, Hölscher AH,

Horneber M, Hübner J, Izbicki JR, Jakobs R, Jenssen C, Kanzler S, Keller M, Kiesslich R,

Klautke G, Körber J, Krause BJ, Kuhn C, Kullmann F, Lang H, Link H, Lordick F, Ludwig

K, Lutz M, Mahlberg R, Malfertheiner P, Merkel S, Messmann H, Meyer HJ, Mönig S,

Piso P, Pistorius S, Porschen R, Rabenstein T, Reichardt P, Ridwelski K, Röcken C,

Roetzer I, Rohr P, Schepp W, Schlag PM, Schmid RM, Schmidberger H, Schmiegel WH,

Schmoll HJ, Schuch G, Schuhmacher C, Schütte K, Schwenk W, Selgrad M, Sendler A,

Seraphin J, Seufferlein T, Stahl M, Stein H, Stoll C, Stuschke M, Tannapfel A, Tholen R,

Thuss-Patience P, Treml K, Vanhoefer U, Vieth M, Vogelsang H, Wagner D, Wedding

U, Weimann A, Wilke H, Wittekind C, AWMF, AWMF: (2011) [German S3-guideline

"Diagnosis and treatment of esophagogastric cancer"]. Z GASTROENTEROL, 49: 461-

531 21476183 IF: 0,896, anteiliger IF: 0,00028

2. Schmoll HJ: (2011) Do we need oncology trials tailored for the elderly or frail?

LANCET, 377: 1725-7 21601694 IF: 38,278, anteiliger IF: 3,8278

3. Schmoll HJ, Hallek M: (2011) Perspectives for onkologie. ONKOLOGIE, 34:

659 22156443 IF: 0,868, anteiliger IF: 0,0434


Comments and Letter

1. Wass M, Behlendorf T, Schädlich B, Mottok A, Rosenwald A, Schmoll HJ, Jordan K:

(2014) Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case

report with a short-term response. EUR J HAEMATOL, 92: 268-70 24330038 IF: 2,066, anteiliger IF: 0,01377


Comments and Letter

1. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, ESMO/ASCO Global Curriculum Working Group: (2016) ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016. ANN ONCOL, 27: 1378-81 IF: 11,855, anteiliger IF: 0,39517

2. Schmoll HJ: (2016) Targeting HER2: precision oncology for colorectal cancer. LANCET ONCOL, 17: 685-686 27108244 IF: 33,9, anteiliger IF: 3,39


Comments and Letter

1. Schmoll HJ: (2017) Selective internal radiotherapy in advanced colorectal cancer: only for right-sided tumours? LANCET ONCOL, 18: 1138-1139 28781172 IF: 33,9, anteiliger IF: 3,39


prof. dr. med. hans-joachim schmoll pubmed 1970 – 2018 · if: 0, anteiliger if: 0 1985 summe...

Documents